<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">75393</article-id><article-id pub-id-type="doi">10.7554/eLife.75393</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Oversized cells activate global proteasome-mediated protein degradation to maintain cell size homeostasis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Shixuan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4972-415X</contrib-id><email>shixuan@stanford.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Ceryl</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9010-9039</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Melo-Gavin</surname><given-names>Chloe</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ginzberg</surname><given-names>Miriam B</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Blutrich</surname><given-names>Ron</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Nish</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rape</surname><given-names>Michael</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4849-6343</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Mark</surname><given-names>Kevin G</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kafri</surname><given-names>Ran</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9656-0189</contrib-id><email>ran.kafri@sickkids.ca</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>Department of Molecular Genetics, University of Toronto</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057q4rt57</institution-id><institution>Cell Biology, The Hospital for Sick Children, Toronto</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Department of Chemical and Systems Biology, Stanford University</institution></institution-wrap><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an7q238</institution-id><institution>Department of Molecular Cell Biology, University of California at Berkeley</institution></institution-wrap><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>Department of Cell Biology, UT Southwestern Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Postovit</surname><given-names>Lynne-Marie</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y72wh86</institution-id><institution>Queens University</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Postovit</surname><given-names>Lynne-Marie</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y72wh86</institution-id><institution>Queens University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>10</day><month>01</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e75393</elocation-id><history><date date-type="received" iso-8601-date="2021-11-26"><day>26</day><month>11</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2024-12-13"><day>13</day><month>12</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-11-11"><day>11</day><month>11</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.11.09.467936"/></event></pub-history><permissions><copyright-statement>© 2025, Liu et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Liu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-75393-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-75393-figures-v2.pdf"/><related-article related-article-type="article-reference" ext-link-type="doi" xlink:href="10.7554/eLife.26957" id="ra1"/><abstract><p>Proliferating animal cells maintain a stable size distribution over generations despite fluctuations in cell growth and division size. Previously, we showed that cell size control involves both cell size checkpoints, which delay cell cycle progression in small cells, and size-dependent regulation of mass accumulation rates (Ginzberg et al., 2018). While we previously identified the p38 MAPK pathway as a key regulator of the mammalian cell size checkpoint (Liu et al., 2018), the mechanism of size-dependent growth rate regulation has remained elusive. Here, we quantified global rates of protein synthesis and degradation in cells of varying sizes, both under unperturbed conditions and in response to perturbations that trigger size-dependent compensatory growth slowdown. We found that protein synthesis rates scale proportionally with cell size across cell cycle stages and experimental conditions. In contrast, oversized cells that undergo compensatory growth slowdown exhibit a superlinear increase in proteasome-mediated protein degradation, with accelerated protein turnover per unit mass, suggesting activation of the proteasomal degradation pathway. Both nascent and long-lived proteins contribute to the elevated protein degradation during compensatory growth slowdown, with long-lived proteins playing a crucial role at the G1/S transition. Notably, large G1/S cells exhibit particularly high efficiency in protein degradation, surpassing that of similarly sized or larger cells in S and G2, coinciding with the timing of the most stringent size control in animal cells. These results collectively suggest that oversized cells reduce their growth efficiency by activating global proteasome-mediated protein degradation to promote cell size homeostasis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cell size</kwd><kwd>cell size homeostasis</kwd><kwd>growth rate compensation</kwd><kwd>proteasome-mediated protein degradation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000038</institution-id><institution>Natural Sciences and Engineering Research Council of Canada</institution></institution-wrap></funding-source><award-id>RGPIN-2015-05805</award-id><principal-award-recipient><name><surname>Kafri</surname><given-names>Ran</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006126</institution-id><institution>Hospital for Sick Children</institution></institution-wrap></funding-source><award-id>Restracomp Graduate Fellowship</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Shixuan</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006126</institution-id><institution>Hospital for Sick Children</institution></institution-wrap></funding-source><award-id>Restracomp Postdoc Fellowship</award-id><principal-award-recipient><name><surname>Ginzberg</surname><given-names>Miriam B</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003579</institution-id><institution>University of Toronto</institution></institution-wrap></funding-source><award-id>Open Fellowship</award-id><principal-award-recipient><name><surname>Tan</surname><given-names>Ceryl</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>F32GM120956</award-id><principal-award-recipient><name><surname>Mark</surname><given-names>Kevin G</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Oversized mammalian cells reduce their growth efficiency by activating global protein degradation, which functions in parallel with the cell size checkpoints, to promote cell size homeostasis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>To maintain cell size homeostasis, proliferating cells double their mass from one division to the next and divide into similarly sized daughter cells. This stringent regulation of cell size exists in wide-ranging systems such as single-celled yeasts (<xref ref-type="bibr" rid="bib23">Hartwell et al., 1974</xref>; <xref ref-type="bibr" rid="bib25">Johnston et al., 1977</xref>; <xref ref-type="bibr" rid="bib47">Nurse, 1975</xref>; <xref ref-type="bibr" rid="bib53">Schmoller et al., 2015</xref>), animal cells in culture and within tissues (<xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Xie and Skotheim, 2020</xref>; <xref ref-type="bibr" rid="bib65">Zatulovskiy et al., 2020</xref>), as well as plant meristem cells (<xref ref-type="bibr" rid="bib14">D’Ario et al., 2021</xref>; <xref ref-type="bibr" rid="bib55">Serrano-Mislata et al., 2015</xref>). Misregulation of cell size control results in increased size heterogeneity, which is typically observed during neoplastic growth and is a hallmark of malignancy in many tumors, including breast cancer and small cell lung cancer (<xref ref-type="bibr" rid="bib4">Asadullah et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Bell and Waizbard, 1986</xref>; <xref ref-type="bibr" rid="bib20">Ginzberg et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Lee et al., 1992</xref>).</p><p>How is cell size controlled and how does cellular growth in mass coordinate with the cell cycle program? A major mechanism is the cell size checkpoint, which hinders cell cycle progression for cells that are smaller than the target size. The mammalian G1/S cell size checkpoint was first reported by Zetterberg and Killander over 50 years ago (<xref ref-type="bibr" rid="bib31">Killander and Zetterberg, 1965</xref>; <xref ref-type="bibr" rid="bib66">Zetterberg and Killander, 1965</xref>). Subsequently, similar size checkpoints have been identified in single-celled yeasts (<xref ref-type="bibr" rid="bib23">Hartwell et al., 1974</xref>; <xref ref-type="bibr" rid="bib47">Nurse, 1975</xref>). In recent years, the functioning of cell size checkpoints has been investigated with increasingly powerful technologies (<xref ref-type="bibr" rid="bib10">Cadart et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">D’Ario et al., 2021</xref>; <xref ref-type="bibr" rid="bib37">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Perez-Gonzalez et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Schmoller et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">Varsano et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Xie and Skotheim, 2020</xref>). With increased resolution, these newer studies directly confirmed that smaller cells spend longer periods of growth in G1, allowing cells to reach the target size as they transition into S phase. Although it is not yet clear how animal cells sense their size, studies have revealed roles for both the p38 MAPK (<xref ref-type="bibr" rid="bib37">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Sellam et al., 2019</xref>) and the CDK4/Rb pathways (<xref ref-type="bibr" rid="bib15">Datar et al., 2000</xref>; <xref ref-type="bibr" rid="bib57">Tan et al., 2021</xref>; <xref ref-type="bibr" rid="bib65">Zatulovskiy et al., 2020</xref>).</p><p>In addition to cell size checkpoints, two independent studies suggest that mammalian cells also employ size-dependent regulation of cellular growth rate (<xref ref-type="bibr" rid="bib10">Cadart et al., 2018</xref>; <xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>). Authors of the studies used different methods to measure the growth of individual cell size throughout the cell cycle and found that the rate of cell growth negatively correlated with cell size at various cell cycle stages. <xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref> further applied chemical and genetic perturbations that slowed down or accelerated cell cycle progression and observed compensatory changes in the rate of cellular growth, which buffered the initial effect on cell size (Figure 1A). For example, cells under CDK2 inhibition were forced to grow for a longer period in G1, resulting in an immediate increase in cell size. Remarkably, cells later compensated for this longer period of growth with slower rates of mass accumulation, resulting in only a small increase in cell size (Figure 1—figure supplement 1). To discriminate this mechanism from <italic>size checkpoints</italic>, we use the term <italic>size-dependent compensatory growth</italic>. Notably, this compensation does not occur with CDK4/6 inhibition (<xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>), which was found to reprogram cells to a larger target size (see <xref ref-type="bibr" rid="bib57">Tan et al., 2021</xref>). Altogether, these studies suggest that cells sense their size to regulate not only cell cycle progression (e.g., cell cycle checkpoints), but also adapt the cell growth program to maintain cell size homeostasis.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>In this study, we ask whether the size-dependent regulation of cellular growth is mediated by protein synthesis or protein degradation. We found that proteasome-mediated global protein degradation, rather than protein synthesis, underlies the size-dependent compensatory growth and functions in parallel with cell size checkpoints to promote cell size homeostasis.</p><p>To reliably induce a compensatory growth slowdown, we utilized a CDK2 inhibitor assay previously established by <xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>. We applied this assay to human retinal pigment epithelial-1 (RPE1) cells, a well-characterized non-transformed epithelial cell line. In this assay, unsynchronized cell populations were treated with a low dose of the CDK2 inhibitor, SNS-032, to induce a longer G1 phase. We optimized a concentration range that inhibits CDK2 function without arresting the cell cycle (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Cells were subsequently fixed at different timepoints and profiled for proliferation rate, cell size, and cell cycle stage. Cell size was measured with Alexa fluorophore-conjugated succinimidyl ester (SE), which reacts with primary amines and quantifies total protein content of the cell as previously described (<xref ref-type="bibr" rid="bib27">Kafri et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Mugahid et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Neurohr et al., 2019</xref>). As shown by <xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>, the temporal influence of CDK2 inhibition on cell size is characterized by a two-stage process: an early response followed by a delayed compensation. Although cell size initially increased for CDK2-inhibited cells as a result of the prolonged cell cycle, it gradually plateaus after ~24 hr due to a compensatory slowdown in growth (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Average rates of cell proliferation and cell growth can be inferred from the dynamics of cell number and cell mass (see ‘Materials and methods’). This revealed that CDK2-inhibited cells initially grew at the same rate as control but later compensated with a 24% reduced rate of mass accumulation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In comparison, rates of cell proliferation remained unchanged (25% lower than control) throughout the experiment (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>). The delayed compensatory slowdown in cellular growth suggests that the influence of CDK2 inhibitor on growth rate is indirect and is mediated by a property that accumulates over time, presumably cell size.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>A quantitative assay for the size-dependent regulation of cellular growth rate.</title><p>(<bold>A</bold>) Schematic showing the model of cell size control as described by <xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>. The solid blue line represents an iso-cell size curve: combinations of cellular growth rates (mass accumulation rates) and cell cycle length that result in the same cell size. The dashed blue lines represent iso-size curves at larger (upper curve) or smaller (lower curve) cell sizes. Perturbations that decrease cellular growth rate (e.g., mTOR inhibition) result in an initial decrease in cell size, followed by an adaptation involving the activation of p38 MAPK pathway (<xref ref-type="bibr" rid="bib37">Liu et al., 2018</xref>) to prolong the cell cycle, preventing further decrease in size (purple cells). Perturbations that lengthen the cell cycle (e.g., CDK2 inhibition) result in an initial increase in cell size, followed by a compensatory slowdown of growth rate that prevents further increase in cell size (red cells). (<bold>B, C</bold>) Bar plots comparing the G1 duration (<bold>B</bold>) and average growth rate (<bold>C</bold>) for control (0.1% v/v DMSO, N = 365 single-cell tracks) and CDK2-inhibited RPE1 cells (20 nM SNS-032, N = 125), measured by time-lapse live-cell imaging. Nuclear area is measured as a proxy of cell size. Error bars represent mean ± 95% CIs. p-values are calculated using two-sample <italic>t</italic>-test. (<bold>D, E</bold>) Average nuclear area as a function of time for control and CDK2-inhibited cells, with growth trajectories either synchronized to the first division/birth (<bold>D</bold>) or the time of G1/S transition (<bold>E</bold>). Shaded areas mark 95% CIs. In (<bold>D</bold>), dashed lines mark the average time of G1/S transition. In (<bold>E</bold>), the solid black line marks the time of G1/S transition, and dashed lines mark the average time of first birth/division. Note that CDK2-inhibited cells had larger initial sizes, progressed through G1/S later, and showed slower growth in size (i.e., shallower slope), compared to the control. Also see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>File contains the source code and source data necessary to generate <xref ref-type="fig" rid="fig1">Figure 1</xref> using Matlab.</title><p>Figure1_Script.m generates <xref ref-type="fig" rid="fig1">Figure 1B-E</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-75393-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>RPE1 cells under CDK2 inhibition compensate for prolonged growth with slower rates of mass accumulation.</title><p>(<bold>A</bold>) Measurements of average cell size (top) measured by a total protein dye (SE) and relative cell count (bottom) at different time points after treatment with the mTORC1 inhibitor rapamycin (70 nM) or CDK2 inhibitor SNS-032 (19 nM), compared to the control (0.1% v/v DMSO). Note the initial cell size changes following mTORC1 or CDK2 inhibition (0 to ~24 hr, period defined as the early stage), and consequent plateauing in cell size (period defined as the late stage). Y-axes are in log scale. Each cell size datapoint is an average from a population of &gt;2000 cells. Values of cell size are normalized to control, such that the average cell size of control populations has the value of 1. Values of cell count are normalized to the cell number at the first time point. Dashed and solid lines represent linear fitting of the early and late stages, respectively. (<bold>B</bold>) Cellular growth rate for control and CDK2-inhibited cells at early and late stages, relative to control, estimated from the same data presented in (<bold>A</bold>). Error bars represent 95% CIs of the fitting. Figure is reproduced from Figure 6A–B from <xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref> to demonstrate the assay.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>File contains the source code and source data necessary to generate <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> using Matlab.</title><p>Figure1S1A_Script.m generates <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>. Figure1S1B_Script.m generates <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-75393-fig1-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig1-figsupp1-v2.tif"/></fig></fig-group><p>What underlies this size-dependent regulation of cell growth? The rate of macromolecular growth depends on the interplay between the biosynthesis and degradation of proteins, lipids, polysaccharides, and other macromolecules (<xref ref-type="bibr" rid="bib2">Alber and Suter, 2019</xref>). In an actively proliferating mammalian cell, proteins represent more than half of the cell’s total dry mass (<xref ref-type="bibr" rid="bib41">Mitchison, 1971</xref>) and are under active turnover (<xref ref-type="bibr" rid="bib19">Ghenim et al., 2021</xref>; <xref ref-type="bibr" rid="bib38">Liu et al., 2020</xref>). Total protein content also linearly scales with the dry mass and volume of cells at different cell cycle stages (<xref ref-type="bibr" rid="bib8">Berenson et al., 2019</xref>; <xref ref-type="bibr" rid="bib27">Kafri et al., 2013</xref>). The balance between protein translation and degradation has been shown to significantly influence cell size in various cell types, including neurons, muscles, and cancer cells (<xref ref-type="bibr" rid="bib1">Acebron et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Franklin and Johnson, 1998</xref>; <xref ref-type="bibr" rid="bib22">Gordon et al., 2013</xref>; <xref ref-type="bibr" rid="bib52">Sandri, 2013</xref>), suggesting a vital role of protein homeostasis in cell size control.</p><sec id="s2-1"><title>A quantitative assay for the size-dependent regulation of cellular growth rate</title><p>To further investigate the robustness of the assay, we employed time-lapse imaging to directly quantify single-cell dynamics of size growth. Using the nuclear area delineated by SiR-DNA as a proxy for cell size, we followed RPE1 cells stably expressing the degron of Geminin fused to a monomeric Azami green (mAG-hGem) (<xref ref-type="bibr" rid="bib51">Sakaue-Sawano et al., 2008</xref>) throughout ~60 hr of SNS-032 treatment. Consistent with results from the fixed cell assay, CDK2 inhibition resulted in a longer G1 phase (+3.5 hr, 32%) and lower growth rates of nuclear size (–21%) (<xref ref-type="fig" rid="fig1">Figure 1B–E</xref>). Although CDK2-inhibited cells had a larger initial size as a result of prolonged growth duration from the previous cycle, they grew slower and became similarly sized as control cells around the G1/S transition, which was apparent when growth trajectories were computationally synchronized to the timing of their G1/S transition (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). These findings provide further evidence for the size-dependent compensation in cell growth. CDK2 inhibition induced prolonged growth duration and an initial increase in cell size, which is then compensated by a delayed response of reduced growth rate, affirming that cellular growth rate is adaptively regulated to maintain cell size homeostasis.</p></sec><sec id="s2-2"><title>Compensatory changes in cellular growth rate are not regulated at the level of global protein synthesis</title><p>Because cell growth reflects the balance between rates of protein synthesis and protein degradation, we first asked whether the compensatory growth slowdown is mediated through reduced rates of protein synthesis in large cells. We used a multiplex, single-cell labeling strategy to jointly profile overall protein synthesis rates, macromolecular protein mass (by SE), and cell cycle state in thousands of asynchronized proliferating cells. To quantify global translation rates, we performed kinetic pulse measurements with a derivatized methionine analog, L-azidohomoalanine (AHA) (<xref ref-type="bibr" rid="bib11">Calve et al., 2016</xref>), which measures the amount of AHA that is incorporated into newly synthesized proteins. We performed an AHA pulse for 3 hr to obtain a high signal-to-noise ratio in a relatively short period of the cell cycle. Treating cells with the protein synthesis inhibitor, cycloheximide (CHX), significantly reduces AHA incorporation (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), confirming the efficacy of the assay.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Global rates of protein synthesis scale with cell size.</title><p>(<bold>A</bold>) Scatterplot showing single-cell measurements of global protein synthesis rates (AHA incorporation) as a function of cell size (SE) for control (0.1% v/v DMSO) and cells under 48 hr treatment of the protein synthesis inhibitor cycloheximide (CHX, 3 µM), the CDK2 inhibitor SNS-032 (25 nM), and the CDK4/6 inhibitor palbociclib (50 nM). Lines show linear fit. Bottom and right panels show histograms of cell size and AHA incorporation, respectively. (<bold>B</bold>) Scatterplots as in panel (A) plotted separately for G1, S, and G2+M phase cells under control or CDK2 inhibition. (<bold>C</bold>) Median rates of protein synthesis for G1, S, and G2+M cells under each of the experimental conditions. Data presented as fold-change over the average of control cells in G1, with error bars indicating ±95% CI, N = 10 replicate wells.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>File contains the source code and source data necessary to generate <xref ref-type="fig" rid="fig2">Figure 2</xref> using Matlab.</title><p>Figure2_Script.m generates <xref ref-type="fig" rid="fig2">Figure 2A-C</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-75393-fig2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig2-v2.tif"/></fig><p>If the compensatory slowdown of growth is driven by slower rates of protein synthesis, larger cells should have lower rates of AHA incorporation. Our results, however, demonstrate the contrary. In unperturbed cells, AHA incorporation levels positively correlated with total protein content (<italic>R</italic> = 0.91) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), indicating a faster rate of protein synthesis in large cells. To test if the positive correlation between cell size and AHA incorporation is cell cycle dependent, we further segregated cells by their cell cycle stage and found that the dependence of AHA incorporation on size was consistent for G1, S, and G2 cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). In all cell cycle stages, larger cells incorporated more AHA per unit time. Markedly, the linear dependence of AHA incorporation on cell size persists across a wide range of sizes, even for cells that are approximately twofold larger, as induced by CDK4/6 inhibition (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><p>Because we did not observe a compensatory slowdown of AHA incorporation in naturally large cells, we next examined whether the compensatory growth slowdown following CDK2 inhibition is regulated at the level of protein synthesis. We employed the same strategy described in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and additionally measured rates of AHA incorporation. CDK2-inhibited cells demonstrated a slight increase in both cell size (~11%) and AHA incorporation (~4%) compared to that of control (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), despite the compensatory slowdown of growth. Consistent with measurements in unperturbed cells, CDK2-inhibited cells maintained a similar linear correlation between cell size and AHA incorporation, both at the single-cell level and across different cell cycle stages (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>), suggesting that the protein synthesis machinery is not affected by CDK2 inhibition throughout the duration of the experiment. Together, results from the AHA pulse experiments suggest that the compensatory growth slowdown in CDK2-inhibited cells is not mediated through a decrease in overall rates of protein synthesis but likely through an increase in overall protein degradation.</p></sec><sec id="s2-3"><title>Large cells have higher rates of global protein degradation</title><p>To measure rates of protein degradation, we implemented a CHX chase assay and quantified the loss of total protein mass over time. In this assay, protein synthesis was inhibited by CHX; therefore, the loss of macromolecular protein mass reflected changes resulting from protein degradation. Interestingly, we observed significantly increased rates of protein degradation in larger cells (80th percentile) compared to smaller cells (20th percentile) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), supporting the hypothesis that large cells may activate global protein degradation to initiate a compensatory growth slowdown.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Large cells have higher rates and efficiency of global protein degradation.</title><p>(<bold>A</bold>) Change in cell size measured by SE for small (20th percentile) and large (80th percentile) G1 cells following treatment with the protein synthesis inhibitor cycloheximide (CHX, 10 µM) compared to time point 0 (0.1% v/v DMSO). Cell size changes are expressed as the fraction of the median size at time point 0. Error bars represent mean ± 95% CI (N = 22 replicate wells). (<bold>B, C</bold>) Proteasome-mediated global protein degradation rate (ΔK48-polyUb, B) and cell size (SE, C) over time in control (0.1% v/v DMSO) and in cells treated with the CDK2 inhibitor SNS-032 (25 nM) for 1, 8, and 24 hr. To measure ΔK48-polyUb, cells were immunostained with a K48 linkage-specific polyubiquitin antibody that quantifies the total K48-linked polyubiquitinated proteins (K48-polyUB). ΔK48-polyUb is defined as the clearance rate of K48-polyUb, calculated as the difference between K48-polyUB measured with or without a short-term (30 min) treatment of the proteasome inhibitor Carfilzomib (CFZ, 8 µM) before fixation. Data presented as mean ± 95% CI, N = 9 replicate wells. (<bold>D</bold>) ΔK48-polyUb as a function of cell size (SE) for control and CDK2-inhibited cells (25 nM SNS-032, 24 hr), separated by cell cycle stage. Values are normalized to the average of control cells in G1. Data presented as mean ± 95% CI, N = 9 replicate wells. Right-tailed two-sample <italic>t</italic>-tests indicate significant increase in ΔK48-polyUb of the SNS-032-treated cells compared to the control across the cell cycle: p-values = 7E-95 (G1), 3E-62 (S), and 3E-72 (G2+M). Dashed line represents 1:1 proportional changes in ΔK48-polyUb and cell size (y = x). Note the proportional changes in ΔK48-polyUb and size for control and disproportionately higher increases in ΔK48-polyUb compared to size for SNS-032 treated cells. (<bold>E</bold>) Quantification of PSMB5 concentrations from six replicates of western blots (see <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5</xref>), presented as fold-change of control. Error bars present mean ± 95% CI. Western blots were loaded with the same amount of cell lysates, thus data shown here reflect PSMB5 levels normalized by cell size. (<bold>F</bold>) Scatterplot of single-cell measurements of total proteasome activity (MV151) as a function of cell size (SE) for control (0.1% v/v DMSO) and bortezomib-treated (1 µM) cells, along with histograms showing distribution of cell size (bottom) and proteasome activity (right). Both measurements are shown as relative values to the average of the control. Note the level of active proteasomes may be negative as the quantification was performed after subtraction of background. Lines show linear fit. (<bold>G</bold>) ΔK48-polyUb for control (0.1% v/v DMSO) and SNS-032 (25 nM, 24 hr) treated cells with or without a short-period (3 hr) treatment of the protein synthesis inhibition CHX (3 µM) before fixation, shown for cells at the G1/S transition. Data presented as mean ± 95% CI. N = 5 and 10 replicate wells, respectively, for conditions with and without CHX. See <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref> for cells at other cell cycle stages.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>File contains the source code and source data necessary to generate <xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> using MATLAB.</title><p>Figure3A_Script.m generates <xref ref-type="fig" rid="fig3">Figure 3</xref>. Figure3S1_Script.m generates <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A-B</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-75393-fig3-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>File contains the source code and source data necessary to generate <xref ref-type="fig" rid="fig3">Figure 3B–D</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>; <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplements 3</xref> and <xref ref-type="fig" rid="fig3s4">4</xref> using MATLAB.</title><p>Figure3BCD_S3_Script.m generates <xref ref-type="fig" rid="fig3">Figure 3B–D</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>. Figure3S2_Script.m generates <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A-B</xref>. Figure3S4_part1_Script.m and Figure3S4_part2_Script.m generate <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4A-I</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-75393-fig3-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>File contains the source code and source data necessary to generate <xref ref-type="fig" rid="fig3">Figure 3E–F</xref>, <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5B</xref> using MATLAB.</title><p>Figure3E_3S5B_Script.m generates <xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5B</xref>. Figure3F_Script.m generates <xref ref-type="fig" rid="fig3">Figure 3F</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-75393-fig3-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>File contains the source code and source data necessary to generate <xref ref-type="fig" rid="fig3">Figure 3G</xref>, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref> using MATLAB.</title><p>Figure3G_3S6_Script.m generates <xref ref-type="fig" rid="fig3">Figure 3G</xref>, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6A–D</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-75393-fig3-data4-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Large cells show increased protein degradation throughout the cell cycle.</title><p>(<bold>A, B</bold>) Changes in cell size (SE) for small (20th percentile) and large (80th percentile) cells following treatment with 10 µM cycloheximide, in S (<bold>A</bold>) or G2+M phase (<bold>B</bold>), compared to time point 0 (0.1% v/v DMSO). Cell size changes are expressed as the fraction of the median size at time point 0. Error bars present mean ± 95% CI across replicate wells (N = 22). See <xref ref-type="fig" rid="fig3">Figure 3A</xref> for cells in G1 phase.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Short treatment of the proteasome inhibitor carfilzomib (CFZ) does not affect cell size or fraction of cells in different cell cycle stages.</title><p>(<bold>A, B</bold>) Bar plots showing cell size (<bold>A</bold>) or fraction of cells in G1, S, and G2 phase (<bold>B</bold>) of control (0.1% v/v DMSO) or cells treated with 30 min of 8 µM CFZ. Error bars present mean ± 95% CI (N = 27 replicate wells).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>CDK2 inhibition increases K48-polyUb turnover across cell cycle stages.</title><p>(<bold>A–C</bold>) Clearance of K48-polyUb (ΔK48-polyUb) for control (0.1% v/v DMSO) and SNS-032 (25 nM) treated cells in G1 (<bold>A</bold>), S (<bold>B</bold>), and G2 (<bold>C</bold>) phase at 1, 8, and 24 hr of treatment. Data presented as mean ± 95% CI, N = 9 replicate wells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Changes in cell size and protein degradation rates in response to other cell cycle perturbations.</title><p>(<bold>A</bold>) The fraction of G1 phase cells in control (0.1% v/v DMSO) and the CDK4/6 inhibitor, palbociclib (50 nM) at 8 and 24 hr of treatment. (<bold>B, C</bold>) ΔK48-polyUb for control and palbociclib-treated cells, separately at 8 (<bold>B</bold>) and 24 (<bold>C</bold>) hr of treatment. Note that CDK4/6 inhibition results in an increase in ΔK48-polyUb, proportional to the increase in cell size. (<bold>D</bold>) The fraction of S phase cells in control (0.1% v/v DMSO) and an inhibitor of S phase progression, JNJ-26854165 (300 nM) at 8 and 24 hr of treatment. (<bold>E, F</bold>) ΔK48-polyUb for control and JNJ-26854165-treated cells, separately at 8 (<bold>B</bold>) and 24 (<bold>C</bold>) hr of treatment. (<bold>G</bold>) The fraction of G2+M phase cells in control (0.1% v/v DMSO) and an inhibitor of mitosis progression, barasertib (25 nM) at 8 and 24 hr of treatment. (<bold>H, I</bold>) ΔK48-polyUb for control and barasertib treated cells, separately at 8 (<bold>B</bold>) and 24 (<bold>C</bold>) hr of treatment. Error bars show mean ± 95% CI. N = 10 and 3 replicate wells, respectively, for the control and drug conditions. Note that JNJ-26854165 (8 hr) and barasertib (24 hr) both result in disproportionately larger increases in ΔK48-polyUb compared to the increases in cell size, suggesting an increased efficiency in protein degradation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig3-figsupp4-v2.tif"/></fig><fig id="fig3s5" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 5.</label><caption><title>CDK2 inhibition does not significantly affect proteasome content per unit mass.</title><p>(<bold>A</bold>) Western blots of CDK2-inhibited cells under 44 hr treatment of either 175 nM PHA848125 (PHA) or 39 nM SNS-032 (SNS). Note that western blot lanes were loaded with lysates of equal protein. Vinculin is shown as a loading control. (<bold>B</bold>) Quantification of PSMB5 levels from six replicates of Western blots, presented as fold-change of control. Data presented as mean ± 95% CI.</p><p><supplementary-material id="fig3s5sdata1"><label>Figure 3—figure supplement 5—source data 1.</label><caption><title>File contains uncropped and labeled gels for <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-75393-fig3-figsupp5-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3s5sdata2"><label>Figure 3—figure supplement 5—source data 2.</label><caption><title>File contains raw unedited gels for <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-75393-fig3-figsupp5-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig3-figsupp5-v2.tif"/></fig><fig id="fig3s6" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 6.</label><caption><title>Size-dependent compensatory degradation involves nascently translated and long-lived proteins.</title><p>(<bold>A–D</bold>) ΔK48-polyUb for control (0.1% v/v DMSO) and SNS-032 (25 nM, 24 hr) treated cells with or without a short-period (3 hr) treatment of the protein synthesis inhibition cycloheximide (CHX, 3 µM) before fixation, separately for cells in G1 (<bold>A</bold>), G1/S transition (<bold>B</bold>), S (<bold>C</bold>), and G2+M (<bold>D</bold>) phase. Data presented as mean ± 95% CI. N = 5 and 10 replicate wells, respectively, for conditions with and without CHX. Note the significant reduction in ΔK48-polyUb after CHX treatment, suggesting that nascent proteins account for a substantial fraction of the proteasomal flux. The difference between SNS-/CHX+vs. SNS+/CHX+conditions reflects the degradation rates of only long-lived proteins.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig3-figsupp6-v2.tif"/></fig></fig-group><p>Proteasome-mediated protein degradation is a major route of protein turnover in non-starved cells (<xref ref-type="bibr" rid="bib33">Lecker et al., 2006</xref>). The major targeting signal for proteasomal degradation is a post-translational modification involving ubiquitin chains linked through Lysine 48 (K48) (<xref ref-type="bibr" rid="bib64">Yau and Rape, 2016</xref>). To further test whether larger cells undergo higher rates of proteasome-mediated degradation, we measured the turnover (i.e., clearance) of K48-linked polyubiquitinated proteins (K48-polyUb) in CDK2 inhibited cells that undergo a compensatory growth slowdown. K48-polyUb turnover rates were quantified as the increase in intracellular pools of K48-polyUb that is caused by a short (30 min) treatment with a potent irreversible proteasome inhibitor, carfilzomib (CFZ). The excess amount of K48-polyUb in CFZ-treated cells compared to that of untreated cells, which we term ΔK48-polyUb, estimates the amount of K48-polyUb proteins that would have been degraded during the 30 min had the proteasome not been inhibited. Cell size and the partitioning of cells into different cell cycle stages were not significantly influenced by the 30 min treatment with CFZ (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Using this method, we measured the rates of proteasome-mediated protein degradation (ΔK48-polyUb) in CDK2-inhibited cells that were induced to undergo a compensatory slowdown of growth. CDK2-inhibited cells showed higher rates of ΔK48-polyUb, affirming a role of proteasomes in compensatory growth. The dependence of compensatory growth on proteasomal degradation is further supported by the temporal similarity of these two processes. Both the slowdown in growth rate and increase in ΔK48-polyUb showed delayed dynamics following CDK2 inhibition. CDK2-inhibited cells had similar ΔK48-polyUb as control during the first 8 hr of treatment, but later showed a significant increase in ΔK48-polyUb at 24 hr, indicating increased rates of protein degradation (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). The enhanced turnover of K48-polyUb proteins aligns temporally with the compensatory growth rate changes observed in CDK2-inhibited cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). This pattern was consistently observed across G1, S, and G2+M phases in CDK2-inhibited cells (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). The delayed kinetics suggest that the increased ΔK48-polyUb is not triggered by the immediate inhibition of CDK2 activity but rather from the buildup of excessive cell mass triggered by the gradual influence of the longer cell cycle. Altogether, these results indicate that the compensatory slowdown of cell growth is mediated by increased clearance of K48-polyUb.</p></sec><sec id="s2-4"><title>Large cells under compensatory growth slowdown have higher rates of protein degradation per unit cellular mass</title><p>Our findings suggest that larger cells have higher rates of protein synthesis as well as higher rates of protein degradation. A simple interpretation of these data would posit that both the rates of protein synthesis and degradation linearly scale with cell size. For example, a cell that increased 50% in size would have a 50% increase in both the rates of protein synthesis and degradation. To examine this quantitative relationship, we calculated fold changes in protein synthesis and degradation as a function of fold changes in cell size. Perturbation of CDK2 activity promotes proportional increases in both cell size and the rate of AHA incorporation across all cell cycle stages (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). However, CDK2-inhibited cells exhibit disproportionately larger changes in protein degradation (ΔK48-polyUb) relative to the changes in cell size, suggesting a superlinear relationship. On average, ΔK48-polyUb increased by ~30% in CDK2-inhibited cells, whereas mean cell size only increased by ~3.4% compared to control (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). This disproportionate increase in degradation rates was consistent across all interphase stages (G1: 44%; S: 42%; G2+M: 31%) (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). These observations highlight an interesting contrast between the cell size dependencies of protein synthesis and degradation. Although larger cells have higher absolute rates of protein synthesis, the rates of AHA incorporation per unit cell mass remain relatively constant across different cell sizes. In contrast, larger cells have higher rates of protein degradation even when quantified per unit cellular mass, suggesting an activation of the protein degradation pathways in large cells, in addition to large cells having more proteins to degrade.</p><p>To explore the specificity of these results, we then examined protein degradation in cells treated with the CDK4/6 inhibitor palbociclib, which induces a larger target size without compensatory growth slowdown (<xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">Tan et al., 2021</xref>). As expected, CDK4/6 inhibition resulted in significant increases in both cell size (G1: 32%; S: 69%; G2+M: 38%) and ΔK48-polyUb (G1: 30%; S: 66%; G2+M: 45%) at 24 hr of treatment (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). However, the increases in ΔK48-polyUb remained proportional to the changes in cell size. Unlike the superlinear increase in ΔK48-polyUb observed in CDK2-inhibited cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), cell size and ΔK48-polyUb under CDK4/6 inhibition followed the same linear relationship as control cells across different cell cycle stages (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). This suggests that compensatory degradation is not triggered merely by shifts in target size.</p><p>Next, we examined additional cell size perturbations to test whether the upregulated protein degradation during compensatory growth slowdown is a general size control mechanism or respond specifically to CDK2 inhibition and prolonged G1. Using data from a previous in-house chemical screen (<xref ref-type="bibr" rid="bib30">Kaufman et al., 2022</xref>), we identified compounds that increase cell size by altering progression rates of different cell cycle stages: JNJ-26854165, which slows S phase progression, and barasertib, which delays mitosis (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). Importantly, the two compounds do not directly disrupt DNA or cytoskeleton integrity (<xref ref-type="bibr" rid="bib6">Bavetsias and Linardopoulos, 2015</xref>; <xref ref-type="bibr" rid="bib26">Jones et al., 2013</xref>). Both compounds led to increased global protein degradation, as measured by ΔK48-polyUb (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). Similar to the effects of CDK2 inhibition, they induced disproportionately higher increases in ΔK48-polyUb relative to the cell size increases, particularly in the affected cell cycle stages. Barasertib-treated G2+M cells exhibited a 10% increase in cell size but a 37% increase in ΔK48-polyUb at 8 hr of treatment, and the superlinear increase in ΔK48-polyUb persisted at 24 hr of treatment (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). JNJ-26854165-treated S phase cells showed a temporary superlinear increase in degradation at 8 hr but not at 24 hr of treatment (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). Taken together, these results suggest that activation of protein degradation serves as a general compensatory mechanism of cell size control in response to prolonged growth periods. Whereas the dynamics of the compensatory degradation may vary, it can be triggered irrespective of the specific cell cycle stage affected.</p></sec><sec id="s2-5"><title>Compensatory growth slowdown involves increased proteasome activity in degrading both newly synthesized and long-lived proteins</title><p>What mediates the size-dependent increase in proteasome-mediated protein degradation? One possibility is that large cells have more proteasomes. To test this, we compared proteasome concentration in control and CDK2-inhibited cells by probing the 20S proteasome subunit β5, PSMB5 (<xref ref-type="bibr" rid="bib50">Russell et al., 1999</xref>). These measurements showed that CDK2-inhibited cells had a similar level of proteasomes per unit mass as control (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5</xref>), suggesting that the total number of proteasomes per cell increases proportionally with cell size in CDK2-inhibited cells. Next, we tested if large cells may activate more proteasomes. It was reported that a fraction of the intracellular proteasomes are catalytically inactive and can be stimulated in response to stress (<xref ref-type="bibr" rid="bib13">Collins and Goldberg, 2017</xref>; <xref ref-type="bibr" rid="bib39">Livneh et al., 2016</xref>). To quantify the levels of active proteasomes in single cells, we used a proteasome activity probe, MV151. MV151 is a fluorescent and cell-permeable proteasome inhibitor that selectively binds to the catalytic core of active proteasomes and provides fluorescence readouts of active proteasomes at single-cell resolution (<xref ref-type="bibr" rid="bib59">Verdoes et al., 2006</xref>). These data revealed a linear correlation between cell size and levels of active proteasomes (<italic>R</italic> = 0.90), suggesting that large cells have proportionately higher levels of active proteasomes (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). As a positive control, the proteasome inhibitor, bortezomib, eliminated the dependence of active proteasomes on cell size. The observation that larger cells have proportionally higher levels of active proteasomes, yet exhibit a superlinear increase in K48-polyUb degradation, suggests that the efficiency of protein degradation per active proteasome may be enhanced, warranting further investigation. An increased degradation efficiency might be achieved through increased efficiency in protein ubiquitination, such as activating E3 ubiquitin ligases that target proteins for degradation.</p><p>What proteins are degraded during compensatory growth slowdown? Previous studies have shown that nascent proteins, or newly synthesized polypeptides, are actively degraded in eukaryotic cells as part of protein quality control (<xref ref-type="bibr" rid="bib62">Wolff et al., 2014</xref>). It has been estimated that up to 15% of nascent chains in human cells are tagged for degradation (<xref ref-type="bibr" rid="bib60">Wang et al., 2013</xref>). To examine if nascent or long-lived proteins are preferentially degraded in large cells, we used CHX to acutely inhibit protein synthesis and then measured K48-polyUb turnover. The comparison between cells with and without CHX treatment allowed distinction between the degradation of nascent (CHX-sensitive) and non-nascent (CHX-insensitive) proteins. As anticipated, CHX treatment significantly reduced ΔK48-polyUb levels (<xref ref-type="fig" rid="fig3">Figure 3G</xref>, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref>), confirming that nascent proteins contribute substantially to proteasomal degradation (<xref ref-type="bibr" rid="bib60">Wang et al., 2013</xref>). We then compared cells with or without CDK2 inhibition, the difference of which reflects the level of size-related compensatory degradation. In the absence of CHX, CDK2 inhibition resulted in significant increases in ΔK48-polyUb across the cell cycle (<xref ref-type="fig" rid="fig3">Figure 3G</xref>, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref>), consistent with previous results. However, in the presence of CHX, the increase in ΔK48-polyUb was primarily observed at the G1/S transition (<xref ref-type="fig" rid="fig3">Figure 3G</xref>, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref>). These results suggest that both nascent and long-lived proteins are targeted for degradation during compensatory growth slowdown, with long-lived proteins playing a crucial role at the G1/S transition.</p></sec><sec id="s2-6"><title>Large cells at the G1/S transition show hyperactive global protein degradation</title><p>To further dissect the cell cycle dependency of the increased global protein degradation observed in large cells, we compared ΔK48-polyUb levels across different cell cycle stages. Strikingly, cells at the G1/S transition exhibit the highest ΔK48-polyUb levels in both control and CDK2-inhibited cells (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). Remarkably, rates of global protein degradation observed in these large G1/S cells surpassed those of similarly sized or even larger cells in S and G2 phases, suggesting a hyperactivation of global protein degradation at the G1/S transition.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Hyperactivation of global protein degradation in naturally large cells at the G1/S transition.</title><p>(<bold>A, B</bold>) ΔK48-polyUb (A) and cell size (SE, B) for control (0.1% v/v DMSO) and cells treated with SNS-032 (25 nM, 24 hr), separated by cell cycle stage. Data presented as median ± 95% CI, N = 9 replicate wells. Lines show linear fit, excluding G1/S data, which deviates from the trend of G1, S, and G2+M cells. (<bold>C</bold>) Single-cell measurements of DNA content (DAPI) and the cell cycle reporter Geminin (mAG-hGem) in an unsynchronized population of proliferating RPE1 cells. Black curve represents an average cell cycle trajectory, which is used to parameterize the progression through the cell cycle into a 1D curve used in panels (D, E) (see ‘Materials and methods’). Red circle highlights the G1/S cells, which are large in size and high in ΔK48-polyUb. (<bold>D</bold>) Single-cell measurements of cell size (shown in log scale) as a function of the cell cycle trajectory (see <bold>C</bold> and ‘Materials and methods’) demonstrated in a scatterplot, overlayed with contour lines representing the calculated joint probability density function, which describes the frequency of cells for every given paired value of cell size and cell cycle stage. (<bold>E</bold>) Heatmap of size-normalized ΔK48-polyUb (see ‘Materials and methods’) overlaid on the density contours as in (<bold>D</bold>). Red arrows point to the large cells at G1/S transition. See <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> for heatmap of non-size-normalized ΔK48-polyUb.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>File contains the source code and source data necessary to generate <xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> using MATLAB.</title><p>Figure4AB_Script.m generates <xref ref-type="fig" rid="fig4">Figure 4A and B</xref>. Figure 4C_Script.m generates <xref ref-type="fig" rid="fig4">Figure 4C</xref>. Figure 4DE_Script.m generates <xref ref-type="fig" rid="fig4">Figure 4D and E</xref>. Figure4S1A_Script.m generates <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>. Figure4S1B_Script.m generates <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-75393-fig4-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Large cells prior to the G1/S transition continue through the cell cycle and show elevated ΔK48-polyUb.</title><p>(<bold>A</bold>) Example single-cell dynamics of nuclear area for small (10th percentile) and large (90th percentile) cells chosen ~2.5 hr before G1/S. Trajectories are smoothed with a moving average filter. (<bold>B</bold>) Heatmap of ΔK48-polyUb (not normalized to size, see ‘Materials and methods’) overlaid on the contour lines from <xref ref-type="fig" rid="fig4">Figure 4D</xref>. See <xref ref-type="fig" rid="fig4">Figure 4B</xref> for ΔK48-polyUb normalized to cell size.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Large cells prior to the G1/S transition show hyperactivated global protein degradation as demonstrated by live-cell imaging.</title><p>(<bold>A, B</bold>) Average growth rate of nuclear area measured by live-cell imaging for control (0.1% v/v DMSO, N = 2,724 single-cell tracks) and mTOR-inhibited (5 nM rapamycin) cells (N = 1172), separately shown for the small (the smallest 1/3) and large (the largest 1/3) cells, at 1.25 hr before or 1 hr after the G1/S transition (<bold>A</bold>) or across the entire cell cycle (<bold>B</bold>). G1/S transition was assigned for each single-cell track based on the dynamics of the cell cycle reporter Geminin, with baseline Geminin levels indicating early G1 phase and rapid increase in Geminin level as the start of the G1/S transition. (<bold>C</bold>) Rates of protein synthesis measured as AHA incorporation for control (0.1% v/v DMSO, N = 88,563 cells) and mTOR-inhibited (10 nM torin2, N = 50,293) cells, separately shown for the small (the smallest 1/3) and large cells (the largest 1/3) in the entire population. Error bars present median ± 95% CI.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>File contains the source code and source data necessary to generate <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref> using Matlab.</title><p>Figure4S2_Script.m generates <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A-C</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-75393-fig4-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig4-figsupp2-v2.tif"/></fig></fig-group><p>To better characterize the cell cycle dynamics of compensatory degradation, we performed pseudo-time trajectory analysis and aligned cells to a continuous cell cycle axis based on their DNA content and the FUCCI cell cycle marker mAG-hGem (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, see ‘Materials and methods’; <xref ref-type="bibr" rid="bib27">Kafri et al., 2013</xref>). This method allowed extraction of average cellular dynamics from single-cell snapshots of fixed steady-state populations (<xref ref-type="bibr" rid="bib27">Kafri et al., 2013</xref>). Interestingly, the analysis revealed a subpopulation of exceptionally large cells at the G1/S transition, often comparable in size or even larger than cells in S and G2 phases (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Time-lapse imaging confirmed that large G1/S cells were not arrested but continued to progress through the cell cycle (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). These large G1/S cells exhibited high levels of ΔK48-polyUb per cell (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), and importantly, the highest levels of ΔK48-polyUb per unit mass (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), further supporting the notion of hyperactive protein degradation in large G1/S cells.</p><p>To further test this observation, we used time-lapse imaging and examined the impact of partial protein synthesis inhibition on cellular growth rates before and after the G1/S transition. We applied mTOR inhibition and measured cellular growth rates separately for small and large cells. Under control conditions, large cells on average grew faster than small cells, both before and after the G1/S transition (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), and when averaged across the entire cell cycle (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), likely due to their higher protein synthesis rates (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). However, upon mTOR inhibition, the cellular growth rates of small and large cells converged before the G1/S transition but not after (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). This convergence occurred despite a proportional decrease in protein synthesis rates by mTOR inhibition for all cells, with large cells continuing to synthesize proteins faster than small cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). These results provide additional evidence that large cells prior to the G1/S transition exhibit elevated rates of protein degradation, which counterbalance the higher protein synthesis rates in large cells.</p><p>In summary, our results demonstrate that large cells exhibit elevated rates of protein degradation throughout interphase, with a particularly pronounced increase in large cells at the G1/S transition. This mechanism may function in conjunction with the cell size checkpoints to promote cell size uniformity.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Cell size is fundamental to cellular physiology as it sets the scale for subcellular compartments, biosynthetic capacity, and cellular function. Evidence of cell size control has been reported from single-celled yeasts to multicellular animals and plants (<xref ref-type="bibr" rid="bib17">Dolznig et al., 2004</xref>; <xref ref-type="bibr" rid="bib23">Hartwell et al., 1974</xref>; <xref ref-type="bibr" rid="bib45">Neufeld et al., 1998</xref>; <xref ref-type="bibr" rid="bib47">Nurse, 1975</xref>; <xref ref-type="bibr" rid="bib61">Willis et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Xie and Skotheim, 2020</xref>; <xref ref-type="bibr" rid="bib66">Zetterberg and Killander, 1965</xref>). The precision with which size is controlled also manifests in the cell size regularity observed in healthy tissues. In contrast, deregulation of size control often signals cancerous growth as many tumors display increased heterogeneity in cell size (<xref ref-type="bibr" rid="bib4">Asadullah et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Bell and Waizbard, 1986</xref>; <xref ref-type="bibr" rid="bib34">Lee et al., 1992</xref>).</p><p>Previous studies on cell size control have predominantly focused on cell size checkpoints, in that a critical size threshold is required for cell cycle progression (<xref ref-type="bibr" rid="bib14">D’Ario et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Sellam et al., 2019</xref>; <xref ref-type="bibr" rid="bib65">Zatulovskiy et al., 2020</xref>). In this study, we investigated size-dependent compensatory growth, which functions independently of cell cycle checkpoints. We employed a CDK2 inhibition assay to trigger compensatory growth, forcing cells to undergo prolonged growth periods, resulting in an initial increase in cell size followed by a delayed compensatory growth slowdown (<xref ref-type="fig" rid="fig1">Figure 1</xref>). We found that the rates of global protein synthesis and degradation increase with cell size in both perturbed and unperturbed conditions (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>). Interestingly, although protein synthesis rates scaled proportionally with cell size, protein degradation rates were disproportionately higher in large CDK2-inhibited cells (i.e., higher rates of protein degradation per unit mass), suggesting active upregulation of the proteasomal degradation pathway (<xref ref-type="fig" rid="fig3">Figure 3</xref>). In contrast, CDK4/6 inhibition, which induces a larger target size without triggering compensatory growth slowdown, exhibited the same linear scaling between cell size and protein degradation rates as in control (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). We also tested two other perturbations that forced overgrowth in cell size by extending S or G2/M phases. Like CDK2 inhibition, these perturbations induced superlinear increases in protein degradation (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>), suggesting that activation of protein degradation functions as a general compensatory mechanism of cell size control in response to prolonged growth periods, irrespective of the specific cell cycle stage affected. Further analysis across the cell cycle highlighted a particularly striking increase in global protein degradation in large cells at the G1/S transition (<xref ref-type="fig" rid="fig4">Figure 4</xref>), consistent with the stringent size control observed at the G1 exit (<xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>; <xref ref-type="bibr" rid="bib66">Zetterberg and Killander, 1965</xref>). Based on these results, we propose a model in which oversized cells reduce their growth efficiency by activating global proteasome-mediated protein degradation to promote cell size homeostasis (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>A model of cell size homeostatic control.</title><p>Control of cell size homeostasis involves negative feedback on both the cell cycle duration and cellular growth rate. The cell cycle arm of the regulation involves activation of the p38 MAPK pathway in small cells that prolongs the growth duration (<xref ref-type="bibr" rid="bib37">Liu et al., 2018</xref>). The growth rate arm of the regulation, investigated here, involves upregulated global protein degradation through the proteasomal degradation pathway that reduces growth efficiency in large cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-fig5-v2.tif"/></fig><p>While this study focused on human RPE1 cells, a non-cancerous epithelial cell line, previous work (<xref ref-type="bibr" rid="bib42">Mu et al., 2020</xref>) on a cancerous mouse lymphocytic leukemia cell line found that large polyploid cells do not reduce growth efficiency compared to smaller diploid cells, suggesting that growth rate regulation may be cell type- and ploidy-dependent. Previous work has also suggested that small cells may accelerate their growth at certain cell cycle stages (<xref ref-type="bibr" rid="bib10">Cadart et al., 2018</xref>; <xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>). It will be interesting to examine in future studies whether the growth acceleration observed in these small cells depends on reduced global protein degradation. High-throughput screens on both animal cells and yeasts identified that small cells activate the stress-responding p38 MAPK (Hog1) pathway to prolong the cell cycle (<xref ref-type="bibr" rid="bib37">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Sellam et al., 2019</xref>). Previous work on p38 also found that activation of the pathway by osmotic stress results in reduced protein degradation and lower proteasome activity (<xref ref-type="bibr" rid="bib35">Lee et al., 2010</xref>), whereas p38 inhibition significantly promoted proteasome activity (<xref ref-type="bibr" rid="bib36">Leestemaker et al., 2017</xref>). These reports suggest an intriguing possibility that the p38 MAPK activation in small cells may function in both the cell size checkpoint and growth rate regulation.</p><p>Our data also suggest hyperactivated rates of global protein degradation in large cells at the G1/S transition (<xref ref-type="fig" rid="fig4">Figure 4</xref>). This suggests that, in addition to accommodating cell size checkpoints, the G1/S transition may also serve as a critical regulatory point for protein degradation and growth rate control. These findings align with previous observation of decreased variability in both cell size and growth rate at the G1/S transition (<xref ref-type="bibr" rid="bib21">Ginzberg et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Kafri et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Son et al., 2012</xref>; <xref ref-type="bibr" rid="bib66">Zetterberg and Killander, 1965</xref>). It is well established that progression through the cell cycle, including the G1/S and G2/M transitions, is controlled by ubiquitin-mediated degradation of cell cycle regulators (<xref ref-type="bibr" rid="bib5">Barr et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Nakayama and Nakayama, 2006</xref>). It will be important in future studies to identify the molecular mechanisms underlying the compensatory protein degradation in large cells. For example, what are the enzymes responsible for the observed increase in K48-linked polyubiquitination in larger cells during the G1/S transition? Are compensatory degradation and cyclin turnover mediated by the same, or separate, factors?</p><p>In this work, we identified a size-dependent regulation of global protein degradation that contributes significantly to proteasome-mediated degradation. We also found that both nascent proteins and long-lived proteins are targeted for degradation during compensatory growth slowdown, with the relative contribution of each depending on the cell cycle stage (<xref ref-type="fig" rid="fig3">Figure 3G</xref>, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref>). While proteasomal degradation of nascent chains is classically associated with protein quality control, our data suggest that cells leverage this pathway to modulate their growth rate and maintain cell size homeostasis. Future work employing dynamic isotopic labeling and quantitative proteomics could provide valuable insights into the degradation rates of specific proteins in this context. Two recent studies <xref ref-type="bibr" rid="bib12">Cheng et al., 2021</xref>; <xref ref-type="bibr" rid="bib32">Lanz et al., 2021</xref> used such an approach and measured individual protein concentrations in cells of different sizes. Proteasome subunits were found at higher concentrations in large cells, consistent with elevated rates of ubiquitylation and protein turnover. Interestingly, components involved in translation show slightly reduced concentrations in large cells. Previous work in yeast <xref ref-type="bibr" rid="bib46">Neurohr et al., 2019</xref> demonstrated that oversized cells show impaired gene expression. If translation integrity is disrupted in large cells, increased levels of ubiquitin-mediated degradation may be required for the clearance of aberrant nascent polypeptides through protein quality control pathways. This is consistent with our finding that nascent proteins can significantly contribute to compensatory degradation.</p><p>Our findings provide mechanistic insight into the process of compensatory growth which, unlike cell size checkpoints, can be employed in the homeostatic size control of nonproliferating cells. This has important implications for understanding how terminally differentiated cells, which constitute the majority of cells in an adult body, maintain their size and function. Maintaining cells within their optimal size range is crucial for cellular and organ function. In adipocytes, the release of fatty acid induced by epinephrine was found to be highly dependent on the cell surface area (<xref ref-type="bibr" rid="bib67">Zinder and Shapiro, 1971</xref>). Pancreatic beta cells undergoing hypertrophy show enhanced insulin secretion and improved glucose homeostasis in vivo (<xref ref-type="bibr" rid="bib24">Helman et al., 2016</xref>). Across tissue types, cells dynamically control their size to modulate cell- and tissue-level functions in response to physiological demand; these include compensatory hypertrophy in pancreatic and hepatic cells (<xref ref-type="bibr" rid="bib16">Dhawan et al., 2007</xref>; <xref ref-type="bibr" rid="bib20">Ginzberg et al., 2015</xref>; <xref ref-type="bibr" rid="bib40">Miettinen et al., 2014</xref>), compensatory renal cell hypertrophy following nephrectomy (<xref ref-type="bibr" rid="bib49">Rojas-Canales et al., 2019</xref>) or increased urine flow (<xref ref-type="bibr" rid="bib9">Boehlke et al., 2010</xref>), growth of neurons (axons) in coordination with animal development (<xref ref-type="bibr" rid="bib3">Albus et al., 2013</xref>), and the likely regulation of functional mass of the hormone-secreting glands in response to stress (<xref ref-type="bibr" rid="bib28">Karin et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Karin et al., 2021</xref>). These examples highlight the importance of cell size control in nonproliferating, differentiated cells. The experimental pipeline used in this study can be adapted to study the roles of protein synthesis and degradation in cell size control of nonproliferating cells, whether certain mechanisms are shared between proliferating and nonproliferating cells, and how these processes affect cellular functions.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><p>This study did not generate new unique reagents. All compounds were purchased from Selleckchem (SNS-032, S1145; palbociclib, S4482; bortezomib, S1013; cycloheximide, S7418; carfilzomib S2853; JNJ-26854165, S1172; barasertib, S1147). Click-IT L-azidohomoalaine was purchased from Thermo Scientific (C10102). The activity-based active proteasome probe (ABP) MV151 Bodipy-TMR was a kind gift from the Florea Lab at Leiden University. The anti-ubiquitin K48-specific antibody (Clone Apu2.07) was a kind gift from Genentech.</p><sec id="s4-1"><title>Cell culture</title><p>This work used human retinal pigmented epithelial (RPE1) obtained from ATCC (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:4388">4388</ext-link>). Cells have been regularly tested for mycoplasma contamination, and no contamination had been detected during the experiments. RPE1 cells with stable expression of the degron of Geminin fused to Azami Green (mAG-hGem) were cultured in DMEM medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Wisent, Montreal, QC) at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. Measurements were generally made when cells were 60–80% confluent to avoid the effects of sparse or dense culture on cell growth and proliferation.</p></sec><sec id="s4-2"><title>Fixation, staining, and imaging</title><p>Cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) for 10 min, followed by permeabilization in cold methanol at –20°C for 5 min. Cells were stained with 0.4 µg/mL Alexa Fluor 647 carboxylic acid, succinimidyl ester (SE-A647, Invitrogen A-20006) for 2 hr at room temperature. The cellular integrated intensity of SE-A647 measures total protein mass, which is proportional to a cell’s dry mass (<xref ref-type="bibr" rid="bib27">Kafri et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Mugahid et al., 2020</xref>). DNA was stained with 1 µg/mL DAPI (Sigma D8417) for 10 min at room temperature. Cells were imaged using the Operetta High-Content Imaging System (PerkinElmer, Woodbridge, ON) at ×20 magnification. Automated image processing was performed as previously described (<xref ref-type="bibr" rid="bib37">Liu et al., 2018</xref>).</p></sec><sec id="s4-3"><title>Time-lapse microscopy and analysis</title><p>RPE1 cells with stable expression of H2B-mTurquoise and Geminin-mVenus were seeded in 96-well μclear microplates (Greiner Bio-one, Monroe, NC) and grown in the incubator for at least 6 hr prior to imaging. The cells were imaged using the Operetta High-Content Imaging System. During imaging, the plate was incubated in a live-cell chamber (37°C, 5% CO<sub>2</sub>), and cells were grown in FluoroBrite DMEM supplemented with FBS, L-glutamine and sodium pyruvate. As the cells were previously cultured in regular DMEM and displayed suboptimal cell proliferation after switching to FluoroBrite DMEM, cells were grown in FluoroBrite medium for a period of 2 weeks to adapt to the new medium before the time-lapse experiments. Widefield fluorescent images of H2B-mTurquoise and Geminin-mVenus were collected every 15 min at ×20 magnification for 60 hr. Under this experimental setting, the microscope could support imaging of up to four wells. To track the movement and division of single cells, and analyze nuclear area dynamics and cell cycle progression, we used the same methods as described previously (<xref ref-type="bibr" rid="bib37">Liu et al., 2018</xref>). Growth rate is estimated as the first derivative of the smoothed nuclear area dynamics, and all measurements presented in the study only examined the cells continuously tracked from one division to the next. The first and last six time points of the cell cycle were removed from the growth rate analysis because of the influence of nuclear breakdown and formation.</p></sec><sec id="s4-4"><title>Cell cycle stages</title><p>Cells were first partitioned, according to their integrated nuclear DNA level, into G1 (2N), S (2N-4N), and G2 (4N) phases. Progression through the G1 phase was further divided, based on the fluorescence of integrated nuclear Geminin, when available, into early G1 (low baseline Geminin) and G1/S transition (higher Geminin). The thresholds were automatically detected based on the distributions of DNA and log(Geminin).</p></sec><sec id="s4-5"><title>Measures of AHA incorporation</title><p>To quantify rates of nascent protein synthesis, cells were treated with the CDK4/6 inhibitor palbociclib (50 nM) or CDK2 inhibitor SNS-032 (25 nM) for 48 hr, then pulse-labeled with Click-IT L-azidohomoalanine (AHA, Invitrogen C10102) for 3 hr as described in the manufacturer’s protocol. Cells were then fixed and stained for DAPI and SE-A647. Rates of AHA incorporation were determined by labeling the cells with Alexa Fluor 488 DIBO alkyne (Invitrogen C10405), followed by imaging and quantification of the integrated intensity of the fluorophore on a single-cell basis as detailed above. As a negative control, cells were treated with 1 µM of the protein synthesis inhibitor CHX.</p></sec><sec id="s4-6"><title>Cycloheximide chase experiment</title><p>Cells were seeded at 1500 cells per well into 96-well Cell Carrier-96 ultra microplates (PerkinElmer) for at least 6 hr prior to treatment. The protein synthesis inhibitor CHX was then administered at 10 µM for either 0, 1.5, 3, 6, or 9 hr. Cells were then fixed and stained for DAPI and SE-A647, and imaged as detailed above. Total protein loss over time was measured by changes in cell size (SE) for the smaller 20% (20th percentile) and the larger 20% (80th percentile) of G1, S, or G2 cells separately.</p></sec><sec id="s4-7"><title>Measurements of active proteasomes</title><p>RPE1-mAG-hGem cells were seeded at 1500 cells per well into 96-well Cell Carrier-96 ultra microplates (PerkinElmer) for at least 6 hr prior to treatment. The cells were then treated with 1 µM activity-based active proteasome probe (ABP) MV151 Bodipy-TMR for 2 hr. MV151 binds to the inside of the catalytic core (20S) of active proteasomes, providing a total fluorescence intensity (per cell) that is proportional to proteasomal activity (<xref ref-type="bibr" rid="bib59">Verdoes et al., 2006</xref>). As a negative control, cells were treated with 1 µM of the proteasome inhibitor bortezomib. Cells were then fixed and stained for DAPI and SE-A647, and imaged as detailed above.</p></sec><sec id="s4-8"><title>Measurements of K48-polyUb turnover</title><p>RPE1-mAG-hGem cells were seeded into 96-well Cell Carrier-96 ultra microplates (PerkinElmer) for at least 6 hr prior to treatment. Cells were then treated with the experimental drugs (e.g., 25 nM SNS-032) or DMSO control (&lt;0.5% v/v) for the intended treatment time as indicated in the figures. At 30 min before fixation, half of the wells of each experimental condition were treated with a proteasome inhibitor (8 µM CFZ). After fixation, cells were immunostained for total levels of K48-linked polyubiquitin with a primary antibody against K48-polyUb chains (Clone Apu2.07, Genentech, 1:500) for 2 hr at room temperature, followed by incubation with a secondary antibody (goat anti-human IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa 555, Thermo Fisher, 1:500) for 30 min at room temperature. Cells were then stained for DAPI and SE-A647, and imaged as detailed above. ΔK48-polyUb is calculated between every pair of CFZ-treated vs. non-CFZ-treated wells of the same experimental condition. Average and CIs of ΔK48-polyUb were then calculated with all replicate measurements of the same condition.</p></sec><sec id="s4-9"><title>Whole-cell lysis and western blotting</title><p>To prepare whole-cell lysates, cells were rinsed with ice-cold PBS and solubilized with RIPA Lysis Buffer (Boston Bio-Products, Boston, MA) (50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, 1% NP-40, 0.1% SDS and 0.5% sodium deoxycholate, pH 7.4) supplemented with protease and phosphatase inhibitor cocktail (Thermo Scientific, Burlington, ON). Protein concentration was determined using the BCA protein assay (Thermo Scientific). Proteins were suspended with 4× Bolt LDS Sample Buffer and 10× Bolt Reducing Agent and heated for 10 min at 70°C. Samples of equal protein were resolved by SDS-polyacrylamide gel electrophoresis and subjected to immunoblotting for proteins as indicated. All western blot results in the figures have been reproduced in replicate experiments with cell lysates samples prepared in independent experiments.</p></sec><sec id="s4-10"><title>Estimation of cell cycle length and growth rate from bulk measurements</title><p>Cells were treated with inhibitors on multiple 96-well plates and fixed every 20 hr over a period of 3 days. The plate slated to be fixed on the last timepoint was imaged by digital phase contrast (Operetta High-Content Imaging System; PerkinElmer) every 12 hr to acquire cell number estimates. Cell size was quantified using the total fluorescence intensity from SE-A647 at a single-cell level. Growth rate and cell cycle length were quantified from population averages of cell size and cell number over time. To quantify cell cycle length (τ), we fit exponential curves to cell number over time <inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>o</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msup><mml:mi>α</mml:mi><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>, where <italic>N<sub>t</sub></italic> is the cell count at time <italic>t</italic> and α = <inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>t</mml:mi></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>. To estimate growth rate (ν), we calculated the rate of increase in bulk mass (<italic>M<sub>t</sub> = cell size × cell count</italic>) of the total population and divided that by the cell number: <italic>ν</italic> = <inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>N</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>. Due to our method of cell size measurement, growth rate quantifications were performed on fixed populations of cells.</p></sec><sec id="s4-11"><title>Estimation of a continuous cell cycle axis</title><p>Single-cell levels of DNA (DAPI) and Geminin (mAG-hGem) were reduced to a single variable (ℓ), which represents a continuous measure of cell cycle stages. See specific algorithm described previously (<xref ref-type="bibr" rid="bib27">Kafri et al., 2013</xref>). In brief, the trajectory is detected as the probability density ridge in the DNA-Geminin distribution, and individual cells were projected to the trajectory through the shortest distance. Note the cell cycle trajectory detected in this study corresponds to an average progression over the cell cycle but does not necessarily reflect the relative duration of each phase.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Reviewing Editor eLife, founder and member of the scientific advisory board of Nurix Therapeutics, a member of the scientific advisory board of Monte Rosa Therapeutics, and an iPartner with The Column Group</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Supervision, Investigation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Supervision, Investigation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Data curation, Supervision, Validation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-75393-transrepform1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data presented in this study are included in the manuscript and supporting files. Source data files have been provided for all figures.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Yifat Merbl, Mikael Bjӧrklund, and members of the Kafri laboratories for helpful discussions. This work was supported by the Natural Sciences and Engineering Research Council of Canada (RGPIN-2015-05805) to RK, the Restracomp Graduate and Postdoctoral Fellowship from the Research Training Center at the Hospital for Sick Children to SL and MBG, the University of Toronto Open Fellowship to CT, and the National Institute of General Medical Sciences of the National Institutes of Health award F32GM120956 to KGM.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acebron</surname><given-names>SP</given-names></name><name><surname>Karaulanov</surname><given-names>E</given-names></name><name><surname>Berger</surname><given-names>BS</given-names></name><name><surname>Huang</surname><given-names>YL</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mitotic wnt signaling promotes protein stabilization and regulates cell size</article-title><source>Molecular Cell</source><volume>54</volume><fpage>663</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.04.014</pub-id><pub-id pub-id-type="pmid">24837680</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alber</surname><given-names>AB</given-names></name><name><surname>Suter</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dynamics of protein synthesis and degradation through the cell cycle</article-title><source>Cell Cycle</source><volume>18</volume><fpage>784</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1080/15384101.2019.1598725</pub-id><pub-id pub-id-type="pmid">30907235</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albus</surname><given-names>CA</given-names></name><name><surname>Rishal</surname><given-names>I</given-names></name><name><surname>Fainzilber</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cell length sensing for neuronal growth control</article-title><source>Trends in Cell Biology</source><volume>23</volume><fpage>305</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2013.02.001</pub-id><pub-id pub-id-type="pmid">23511112</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asadullah</surname><given-names>KS</given-names></name><name><surname>Saxena</surname><given-names>N</given-names></name><name><surname>Sarkar</surname><given-names>M</given-names></name><name><surname>Barai</surname><given-names>A</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Combined heterogeneity in cell size and deformability promotes cancer invasiveness</article-title><source>Journal of Cell Science</source><volume>134</volume><elocation-id>jcs250225</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.250225</pub-id><pub-id pub-id-type="pmid">33602741</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>AR</given-names></name><name><surname>Heldt</surname><given-names>FS</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Bakal</surname><given-names>C</given-names></name><name><surname>Novák</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A dynamical framework for the all-or-none G1/S transition</article-title><source>Cell Systems</source><volume>2</volume><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2016.01.001</pub-id><pub-id pub-id-type="pmid">27136687</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bavetsias</surname><given-names>V</given-names></name><name><surname>Linardopoulos</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Aurora kinase inhibitors: current status and outlook</article-title><source>Frontiers in Oncology</source><volume>5</volume><elocation-id>e278</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2015.00278</pub-id><pub-id pub-id-type="pmid">26734566</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>CD</given-names></name><name><surname>Waizbard</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Variability of cell size in primary and metastatic human breast carcinoma</article-title><source>Invasion &amp; Metastasis</source><volume>6</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">3941026</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berenson</surname><given-names>DF</given-names></name><name><surname>Zatulovskiy</surname><given-names>E</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Skotheim</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Constitutive expression of a fluorescent protein reports the size of live human cells</article-title><source>Molecular Biology of the Cell</source><volume>30</volume><fpage>2985</fpage><lpage>2995</lpage><pub-id pub-id-type="doi">10.1091/mbc.E19-03-0171</pub-id><pub-id pub-id-type="pmid">31599704</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehlke</surname><given-names>C</given-names></name><name><surname>Kotsis</surname><given-names>F</given-names></name><name><surname>Patel</surname><given-names>V</given-names></name><name><surname>Braeg</surname><given-names>S</given-names></name><name><surname>Voelker</surname><given-names>H</given-names></name><name><surname>Bredt</surname><given-names>S</given-names></name><name><surname>Beyer</surname><given-names>T</given-names></name><name><surname>Janusch</surname><given-names>H</given-names></name><name><surname>Hamann</surname><given-names>C</given-names></name><name><surname>Gödel</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>K</given-names></name><name><surname>Herbst</surname><given-names>M</given-names></name><name><surname>Hornung</surname><given-names>M</given-names></name><name><surname>Doerken</surname><given-names>M</given-names></name><name><surname>Köttgen</surname><given-names>M</given-names></name><name><surname>Nitschke</surname><given-names>R</given-names></name><name><surname>Igarashi</surname><given-names>P</given-names></name><name><surname>Walz</surname><given-names>G</given-names></name><name><surname>Kuehn</surname><given-names>EW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Primary cilia regulate mTORC1 activity and cell size through Lkb1</article-title><source>Nature Cell Biology</source><volume>12</volume><fpage>1115</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1038/ncb2117</pub-id><pub-id pub-id-type="pmid">20972424</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadart</surname><given-names>C</given-names></name><name><surname>Monnier</surname><given-names>S</given-names></name><name><surname>Grilli</surname><given-names>J</given-names></name><name><surname>Sáez</surname><given-names>PJ</given-names></name><name><surname>Srivastava</surname><given-names>N</given-names></name><name><surname>Attia</surname><given-names>R</given-names></name><name><surname>Terriac</surname><given-names>E</given-names></name><name><surname>Baum</surname><given-names>B</given-names></name><name><surname>Cosentino-Lagomarsino</surname><given-names>M</given-names></name><name><surname>Piel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Size control in mammalian cells involves modulation of both growth rate and cell cycle duration</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>e3275</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05393-0</pub-id><pub-id pub-id-type="pmid">30115907</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calve</surname><given-names>S</given-names></name><name><surname>Witten</surname><given-names>AJ</given-names></name><name><surname>Ocken</surname><given-names>AR</given-names></name><name><surname>Kinzer-Ursem</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Incorporation of non-canonical amino acids into the developing murine proteome</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>32377</elocation-id><pub-id pub-id-type="doi">10.1038/srep32377</pub-id><pub-id pub-id-type="pmid">27572480</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Kafri</surname><given-names>R</given-names></name><name><surname>Björklund</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Size-scaling promotes senescence-like changes in proteome and organelle content</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.08.05.455193</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>GA</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The logic of the 26S proteasome</article-title><source>Cell</source><volume>169</volume><fpage>792</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.04.023</pub-id><pub-id pub-id-type="pmid">28525752</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Ario</surname><given-names>M</given-names></name><name><surname>Tavares</surname><given-names>R</given-names></name><name><surname>Schiessl</surname><given-names>K</given-names></name><name><surname>Desvoyes</surname><given-names>B</given-names></name><name><surname>Gutierrez</surname><given-names>C</given-names></name><name><surname>Howard</surname><given-names>M</given-names></name><name><surname>Sablowski</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cell size controlled in plants using DNA content as an internal scale</article-title><source>Science</source><volume>372</volume><fpage>1176</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1126/science.abb4348</pub-id><pub-id pub-id-type="pmid">34112688</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datar</surname><given-names>SA</given-names></name><name><surname>Jacobs</surname><given-names>HW</given-names></name><name><surname>de la Cruz</surname><given-names>AF</given-names></name><name><surname>Lehner</surname><given-names>CF</given-names></name><name><surname>Edgar</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The <italic>Drosophila</italic> cyclin D-Cdk4 complex promotes cellular growth</article-title><source>The EMBO Journal</source><volume>19</volume><fpage>4543</fpage><lpage>4554</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.17.4543</pub-id><pub-id pub-id-type="pmid">10970848</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhawan</surname><given-names>S</given-names></name><name><surname>Georgia</surname><given-names>S</given-names></name><name><surname>Bhushan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Formation and regeneration of the endocrine pancreas</article-title><source>Current Opinion in Cell Biology</source><volume>19</volume><fpage>634</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2007.09.015</pub-id><pub-id pub-id-type="pmid">18061427</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolznig</surname><given-names>H</given-names></name><name><surname>Grebien</surname><given-names>F</given-names></name><name><surname>Sauer</surname><given-names>T</given-names></name><name><surname>Beug</surname><given-names>H</given-names></name><name><surname>Müllner</surname><given-names>EW</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Evidence for a size-sensing mechanism in animal cells</article-title><source>Nature Cell Biology</source><volume>6</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1038/ncb1166</pub-id><pub-id pub-id-type="pmid">15322555</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname><given-names>JL</given-names></name><name><surname>Johnson</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Control of neuronal size homeostasis by trophic factor-mediated coupling of protein degradation to protein synthesis</article-title><source>The Journal of Cell Biology</source><volume>142</volume><fpage>1313</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1083/jcb.142.5.1313</pub-id><pub-id pub-id-type="pmid">9732291</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghenim</surname><given-names>L</given-names></name><name><surname>Allier</surname><given-names>C</given-names></name><name><surname>Obeid</surname><given-names>P</given-names></name><name><surname>Hervé</surname><given-names>L</given-names></name><name><surname>Fortin</surname><given-names>JY</given-names></name><name><surname>Balakirev</surname><given-names>M</given-names></name><name><surname>Gidrol</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A new ultradian rhythm in mammalian cell dry mass observed by holography</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>1290</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-79661-9</pub-id><pub-id pub-id-type="pmid">33446678</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginzberg</surname><given-names>MB</given-names></name><name><surname>Kafri</surname><given-names>R</given-names></name><name><surname>Kirschner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell biology: on being the right (cell) size</article-title><source>Science</source><volume>348</volume><elocation-id>1245075</elocation-id><pub-id pub-id-type="doi">10.1126/science.1245075</pub-id><pub-id pub-id-type="pmid">25977557</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginzberg</surname><given-names>MB</given-names></name><name><surname>Chang</surname><given-names>N</given-names></name><name><surname>D’Souza</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Kafri</surname><given-names>R</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cell size sensing in animal cells coordinates anabolic growth rates and cell cycle progression to maintain cell size uniformity</article-title><source>eLife</source><volume>7</volume><elocation-id>e26957</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.26957</pub-id><pub-id pub-id-type="pmid">29889021</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>BS</given-names></name><name><surname>Kelleher</surname><given-names>AR</given-names></name><name><surname>Kimball</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulation of muscle protein synthesis and the effects of catabolic states</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>45</volume><fpage>2147</fpage><lpage>2157</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2013.05.039</pub-id><pub-id pub-id-type="pmid">23769967</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartwell</surname><given-names>LH</given-names></name><name><surname>Culotti</surname><given-names>J</given-names></name><name><surname>Pringle</surname><given-names>JR</given-names></name><name><surname>Reid</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="1974">1974</year><article-title>Genetic control of the cell division cycle in yeast</article-title><source>Science</source><volume>183</volume><fpage>46</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1126/science.183.4120.46</pub-id><pub-id pub-id-type="pmid">4587263</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helman</surname><given-names>A</given-names></name><name><surname>Klochendler</surname><given-names>A</given-names></name><name><surname>Azazmeh</surname><given-names>N</given-names></name><name><surname>Gabai</surname><given-names>Y</given-names></name><name><surname>Horwitz</surname><given-names>E</given-names></name><name><surname>Anzi</surname><given-names>S</given-names></name><name><surname>Swisa</surname><given-names>A</given-names></name><name><surname>Condiotti</surname><given-names>R</given-names></name><name><surname>Granit</surname><given-names>RZ</given-names></name><name><surname>Nevo</surname><given-names>Y</given-names></name><name><surname>Fixler</surname><given-names>Y</given-names></name><name><surname>Shreibman</surname><given-names>D</given-names></name><name><surname>Zamir</surname><given-names>A</given-names></name><name><surname>Tornovsky-Babeay</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Glaser</surname><given-names>B</given-names></name><name><surname>Powers</surname><given-names>AC</given-names></name><name><surname>Shapiro</surname><given-names>AMJ</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name><name><surname>Dor</surname><given-names>Y</given-names></name><name><surname>Ben-Porath</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>p16(Ink4a)-induced senescence of pancreatic beta cells enhances insulin secretion</article-title><source>Nature Medicine</source><volume>22</volume><fpage>412</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1038/nm.4054</pub-id><pub-id pub-id-type="pmid">26950362</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>G</given-names></name><name><surname>Pringle</surname><given-names>J</given-names></name><name><surname>Hartwell</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1977">1977</year><article-title>Coordination of growth with cell division in the yeast</article-title><source>Experimental Cell Research</source><volume>105</volume><fpage>79</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/0014-4827(77)90154-9</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RJ</given-names></name><name><surname>Gu</surname><given-names>D</given-names></name><name><surname>Bjorklund</surname><given-names>CC</given-names></name><name><surname>Kuiatse</surname><given-names>I</given-names></name><name><surname>Remaley</surname><given-names>AT</given-names></name><name><surname>Bashir</surname><given-names>T</given-names></name><name><surname>Vreys</surname><given-names>V</given-names></name><name><surname>Orlowski</surname><given-names>RZ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>346</volume><fpage>381</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1124/jpet.113.204958</pub-id><pub-id pub-id-type="pmid">23820125</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kafri</surname><given-names>R</given-names></name><name><surname>Levy</surname><given-names>J</given-names></name><name><surname>Ginzberg</surname><given-names>MB</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Lahav</surname><given-names>G</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dynamics extracted from fixed cells reveal feedback linking cell growth to cell cycle</article-title><source>Nature</source><volume>494</volume><fpage>480</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1038/nature11897</pub-id><pub-id pub-id-type="pmid">23446419</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karin</surname><given-names>O</given-names></name><name><surname>Raz</surname><given-names>M</given-names></name><name><surname>Tendler</surname><given-names>A</given-names></name><name><surname>Bar</surname><given-names>A</given-names></name><name><surname>Korem Kohanim</surname><given-names>Y</given-names></name><name><surname>Milo</surname><given-names>T</given-names></name><name><surname>Alon</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A new model for the HPA axis explains dysregulation of stress hormones on the timescale of weeks</article-title><source>Molecular Systems Biology</source><volume>16</volume><elocation-id>e9510</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20209510</pub-id><pub-id pub-id-type="pmid">32672906</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karin</surname><given-names>O</given-names></name><name><surname>Raz</surname><given-names>M</given-names></name><name><surname>Alon</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An opponent process for alcohol addiction based on changes in endocrine gland mass</article-title><source>iScience</source><volume>24</volume><elocation-id>102127</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.102127</pub-id><pub-id pub-id-type="pmid">33665551</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>T</given-names></name><name><surname>Nitzan</surname><given-names>E</given-names></name><name><surname>Firestein</surname><given-names>N</given-names></name><name><surname>Ginzberg</surname><given-names>MB</given-names></name><name><surname>Iyengar</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Ben-Hamo</surname><given-names>R</given-names></name><name><surname>Porat</surname><given-names>Z</given-names></name><name><surname>Hunter</surname><given-names>J</given-names></name><name><surname>Hilfinger</surname><given-names>A</given-names></name><name><surname>Rotter</surname><given-names>V</given-names></name><name><surname>Kafri</surname><given-names>R</given-names></name><name><surname>Straussman</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Visual barcodes for clonal-multiplexing of live microscopy-based assays</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>2725</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-30008-0</pub-id><pub-id pub-id-type="pmid">35585055</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killander</surname><given-names>D</given-names></name><name><surname>Zetterberg</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1965">1965</year><article-title>A quantitative cytochemical investigation of the relationship between cell mass and initiation of DNA synthesis in mouse fibroblasts in vitro</article-title><source>Experimental Cell Research</source><volume>40</volume><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/0014-4827(65)90285-5</pub-id><pub-id pub-id-type="pmid">5838935</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Lanz</surname><given-names>MC</given-names></name><name><surname>Zatulovskiy</surname><given-names>E</given-names></name><name><surname>Swaffer</surname><given-names>MP</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ilerten</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>You</surname><given-names>DS</given-names></name><name><surname>Marinov</surname><given-names>G</given-names></name><name><surname>McAlpine</surname><given-names>P</given-names></name><name><surname>Elias</surname><given-names>JE</given-names></name><name><surname>Skotheim</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Increasing cell size remodels the proteome and promotes senescence</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.07.29.454227</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Protein degradation by the ubiquitin-proteasome pathway in normal and disease states</article-title><source>Journal of the American Society of Nephrology</source><volume>17</volume><fpage>1807</fpage><lpage>1819</lpage><pub-id pub-id-type="doi">10.1681/ASN.2006010083</pub-id><pub-id pub-id-type="pmid">16738015</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>TK</given-names></name><name><surname>Esinhart</surname><given-names>JD</given-names></name><name><surname>Blackburn</surname><given-names>LD</given-names></name><name><surname>Silverman</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The size of small cell lung carcinoma cells. Ratio to lymphocytes and correlation with specimen size and crush artifact</article-title><source>Analytical and Quantitative Cytology and Histology</source><volume>14</volume><fpage>32</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">1313679</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Yoon</surname><given-names>SK</given-names></name><name><surname>Yoon</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Osmotic stress inhibits proteasome by p38 MAPK-dependent phosphorylation</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>41280</fpage><lpage>41289</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.182188</pub-id><pub-id pub-id-type="pmid">21044959</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leestemaker</surname><given-names>Y</given-names></name><name><surname>de Jong</surname><given-names>A</given-names></name><name><surname>Witting</surname><given-names>KF</given-names></name><name><surname>Penning</surname><given-names>R</given-names></name><name><surname>Schuurman</surname><given-names>K</given-names></name><name><surname>Rodenko</surname><given-names>B</given-names></name><name><surname>Zaal</surname><given-names>EA</given-names></name><name><surname>van de Kooij</surname><given-names>B</given-names></name><name><surname>Laufer</surname><given-names>S</given-names></name><name><surname>Heck</surname><given-names>AJR</given-names></name><name><surname>Borst</surname><given-names>J</given-names></name><name><surname>Scheper</surname><given-names>W</given-names></name><name><surname>Berkers</surname><given-names>CR</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Proteasome activation by small molecules</article-title><source>Cell Chemical Biology</source><volume>24</volume><fpage>725</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2017.05.010</pub-id><pub-id pub-id-type="pmid">28552582</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Ginzberg</surname><given-names>MB</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Hild</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Chang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Diena</surname><given-names>S</given-names></name><name><surname>Trimble</surname><given-names>W</given-names></name><name><surname>Wasserman</surname><given-names>L</given-names></name><name><surname>Jenkins</surname><given-names>JL</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name><name><surname>Kafri</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Size uniformity of animal cells is actively maintained by a p38 MAPK-dependent regulation of G1-length</article-title><source>eLife</source><volume>7</volume><elocation-id>e26947</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.26947</pub-id><pub-id pub-id-type="pmid">29595474</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Peshkin</surname><given-names>L</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Computationally enhanced quantitative phase microscopy reveals autonomous oscillations in mammalian cell growth</article-title><source>PNAS</source><volume>117</volume><fpage>27388</fpage><lpage>27399</lpage><pub-id pub-id-type="doi">10.1073/pnas.2002152117</pub-id><pub-id pub-id-type="pmid">33087574</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livneh</surname><given-names>I</given-names></name><name><surname>Cohen-Kaplan</surname><given-names>V</given-names></name><name><surname>Cohen-Rosenzweig</surname><given-names>C</given-names></name><name><surname>Avni</surname><given-names>N</given-names></name><name><surname>Ciechanover</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death</article-title><source>Cell Research</source><volume>26</volume><fpage>869</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1038/cr.2016.86</pub-id><pub-id pub-id-type="pmid">27444871</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>TP</given-names></name><name><surname>Pessa</surname><given-names>HKJ</given-names></name><name><surname>Caldez</surname><given-names>MJ</given-names></name><name><surname>Fuhrer</surname><given-names>T</given-names></name><name><surname>Diril</surname><given-names>MK</given-names></name><name><surname>Sauer</surname><given-names>U</given-names></name><name><surname>Kaldis</surname><given-names>P</given-names></name><name><surname>Björklund</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of transcriptional and metabolic programs related to mammalian cell size</article-title><source>Current Biology</source><volume>24</volume><fpage>598</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2014.01.071</pub-id><pub-id pub-id-type="pmid">24613310</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mitchison</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1971">1971</year><source>The Biology of the Cell Cycle</source><publisher-name>CUP Archive</publisher-name></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname><given-names>L</given-names></name><name><surname>Kang</surname><given-names>JH</given-names></name><name><surname>Olcum</surname><given-names>S</given-names></name><name><surname>Payer</surname><given-names>KR</given-names></name><name><surname>Calistri</surname><given-names>NL</given-names></name><name><surname>Kimmerling</surname><given-names>RJ</given-names></name><name><surname>Manalis</surname><given-names>SR</given-names></name><name><surname>Miettinen</surname><given-names>TP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mass measurements during lymphocytic leukemia cell polyploidization decouple cell cycle- and cell size-dependent growth</article-title><source>PNAS</source><volume>117</volume><fpage>15659</fpage><lpage>15665</lpage><pub-id pub-id-type="doi">10.1073/pnas.1922197117</pub-id><pub-id pub-id-type="pmid">32581119</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mugahid</surname><given-names>D</given-names></name><name><surname>Kalocsay</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Gruver</surname><given-names>JS</given-names></name><name><surname>Peshkin</surname><given-names>L</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>YAP regulates cell size and growth dynamics via non-cell autonomous mediators</article-title><source>eLife</source><volume>9</volume><elocation-id>e53404</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.53404</pub-id><pub-id pub-id-type="pmid">31913124</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>KI</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Ubiquitin ligases: cell-cycle control and cancer</article-title><source>Nature Reviews. Cancer</source><volume>6</volume><fpage>369</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1038/nrc1881</pub-id><pub-id pub-id-type="pmid">16633365</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neufeld</surname><given-names>TP</given-names></name><name><surname>de la Cruz</surname><given-names>AF</given-names></name><name><surname>Johnston</surname><given-names>LA</given-names></name><name><surname>Edgar</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Coordination of growth and cell division in the <italic>Drosophila</italic> wing</article-title><source>Cell</source><volume>93</volume><fpage>1183</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81462-2</pub-id><pub-id pub-id-type="pmid">9657151</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neurohr</surname><given-names>GE</given-names></name><name><surname>Terry</surname><given-names>RL</given-names></name><name><surname>Lengefeld</surname><given-names>J</given-names></name><name><surname>Bonney</surname><given-names>M</given-names></name><name><surname>Brittingham</surname><given-names>GP</given-names></name><name><surname>Moretto</surname><given-names>F</given-names></name><name><surname>Miettinen</surname><given-names>TP</given-names></name><name><surname>Vaites</surname><given-names>LP</given-names></name><name><surname>Soares</surname><given-names>LM</given-names></name><name><surname>Paulo</surname><given-names>JA</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name><name><surname>Buratowski</surname><given-names>S</given-names></name><name><surname>Manalis</surname><given-names>S</given-names></name><name><surname>van Werven</surname><given-names>FJ</given-names></name><name><surname>Holt</surname><given-names>LJ</given-names></name><name><surname>Amon</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Excessive cell growth causes cytoplasm dilution and contributes to senescence</article-title><source>Cell</source><volume>176</volume><fpage>1083</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.01.018</pub-id><pub-id pub-id-type="pmid">30739799</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurse</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>Genetic control of cell size at cell division in yeast</article-title><source>Nature</source><volume>256</volume><fpage>547</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/256547a0</pub-id><pub-id pub-id-type="pmid">1165770</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Gonzalez</surname><given-names>NA</given-names></name><name><surname>Rochman</surname><given-names>ND</given-names></name><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><name><surname>Le</surname><given-names>M-TT</given-names></name><name><surname>Flanary</surname><given-names>S</given-names></name><name><surname>Sablich</surname><given-names>L</given-names></name><name><surname>Toler</surname><given-names>B</given-names></name><name><surname>Crentsil</surname><given-names>E</given-names></name><name><surname>Takaesu</surname><given-names>F</given-names></name><name><surname>Lambrus</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>V</given-names></name><name><surname>Chengappa</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>TM</given-names></name><name><surname>Holland</surname><given-names>AJ</given-names></name><name><surname>An</surname><given-names>S</given-names></name><name><surname>Wirtz</surname><given-names>D</given-names></name><name><surname>Petrie</surname><given-names>RJ</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name><name><surname>Sun</surname><given-names>SX</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>YAP and TAZ regulate cell volume</article-title><source>The Journal of Cell Biology</source><volume>218</volume><fpage>3472</fpage><lpage>3488</lpage><pub-id pub-id-type="doi">10.1083/jcb.201902067</pub-id><pub-id pub-id-type="pmid">31481532</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas-Canales</surname><given-names>DM</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Makuei</surname><given-names>L</given-names></name><name><surname>Gleadle</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Compensatory renal hypertrophy following nephrectomy: when and how?</article-title><source>Nephrology</source><volume>24</volume><fpage>1225</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1111/nep.13578</pub-id><pub-id pub-id-type="pmid">30809888</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>SJ</given-names></name><name><surname>Steger</surname><given-names>KA</given-names></name><name><surname>Johnston</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Subcellular localization, stoichiometry, and protein levels of 26 S proteasome subunits in yeast</article-title><source>The Journal of Biological Chemistry</source><volume>274</volume><fpage>21943</fpage><lpage>21952</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.31.21943</pub-id><pub-id pub-id-type="pmid">10419517</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaue-Sawano</surname><given-names>A</given-names></name><name><surname>Kurokawa</surname><given-names>H</given-names></name><name><surname>Morimura</surname><given-names>T</given-names></name><name><surname>Hanyu</surname><given-names>A</given-names></name><name><surname>Hama</surname><given-names>H</given-names></name><name><surname>Osawa</surname><given-names>H</given-names></name><name><surname>Kashiwagi</surname><given-names>S</given-names></name><name><surname>Fukami</surname><given-names>K</given-names></name><name><surname>Miyata</surname><given-names>T</given-names></name><name><surname>Miyoshi</surname><given-names>H</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Masai</surname><given-names>H</given-names></name><name><surname>Miyawaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Visualizing spatiotemporal dynamics of multicellular cell-cycle progression</article-title><source>Cell</source><volume>132</volume><fpage>487</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.12.033</pub-id><pub-id pub-id-type="pmid">18267078</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandri</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>45</volume><fpage>2121</fpage><lpage>2129</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2013.04.023</pub-id><pub-id pub-id-type="pmid">23665154</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmoller</surname><given-names>KM</given-names></name><name><surname>Turner</surname><given-names>JJ</given-names></name><name><surname>Kõivomägi</surname><given-names>M</given-names></name><name><surname>Skotheim</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dilution of the cell cycle inhibitor Whi5 controls budding-yeast cell size</article-title><source>Nature</source><volume>526</volume><fpage>268</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1038/nature14908</pub-id><pub-id pub-id-type="pmid">26390151</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellam</surname><given-names>A</given-names></name><name><surname>Chaillot</surname><given-names>J</given-names></name><name><surname>Mallick</surname><given-names>J</given-names></name><name><surname>Tebbji</surname><given-names>F</given-names></name><name><surname>Richard Albert</surname><given-names>J</given-names></name><name><surname>Cook</surname><given-names>MA</given-names></name><name><surname>Tyers</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The p38/HOG stress-activated protein kinase network couples growth to division in Candida albicans</article-title><source>PLOS Genetics</source><volume>15</volume><elocation-id>e1008052</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1008052</pub-id><pub-id pub-id-type="pmid">30921326</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano-Mislata</surname><given-names>A</given-names></name><name><surname>Schiessl</surname><given-names>K</given-names></name><name><surname>Sablowski</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Active control of cell size generates spatial detail during plant organogenesis</article-title><source>Current Biology</source><volume>25</volume><fpage>2991</fpage><lpage>2996</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2015.10.008</pub-id><pub-id pub-id-type="pmid">26526374</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Son</surname><given-names>S</given-names></name><name><surname>Tzur</surname><given-names>A</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><name><surname>Jorgensen</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name><name><surname>Manalis</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Direct observation of mammalian cell growth and size regulation</article-title><source>Nature Methods</source><volume>9</volume><fpage>910</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2133</pub-id><pub-id pub-id-type="pmid">22863882</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Ginzberg</surname><given-names>MB</given-names></name><name><surname>Webster</surname><given-names>R</given-names></name><name><surname>Iyengar</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Papadopoli</surname><given-names>D</given-names></name><name><surname>Concannon</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Auld</surname><given-names>DS</given-names></name><name><surname>Jenkins</surname><given-names>JL</given-names></name><name><surname>Rost</surname><given-names>H</given-names></name><name><surname>Topisirovic</surname><given-names>I</given-names></name><name><surname>Hilfinger</surname><given-names>A</given-names></name><name><surname>Derry</surname><given-names>WB</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Kafri</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cell size homeostasis is maintained by CDK4-dependent activation of p38 MAPK</article-title><source>Developmental Cell</source><volume>56</volume><fpage>1756</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2021.04.030</pub-id><pub-id pub-id-type="pmid">34022133</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varsano</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>probing mammalian cell size homeostasis by channel-assisted cell reshaping</article-title><source>Cell Reports</source><volume>20</volume><fpage>397</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.06.057</pub-id><pub-id pub-id-type="pmid">28700941</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdoes</surname><given-names>M</given-names></name><name><surname>Florea</surname><given-names>BI</given-names></name><name><surname>Menendez-Benito</surname><given-names>V</given-names></name><name><surname>Maynard</surname><given-names>CJ</given-names></name><name><surname>Witte</surname><given-names>MD</given-names></name><name><surname>van der Linden</surname><given-names>WA</given-names></name><name><surname>van den Nieuwendijk</surname><given-names>AMCH</given-names></name><name><surname>Hofmann</surname><given-names>T</given-names></name><name><surname>Berkers</surname><given-names>CR</given-names></name><name><surname>van Leeuwen</surname><given-names>FWB</given-names></name><name><surname>Groothuis</surname><given-names>TA</given-names></name><name><surname>Leeuwenburgh</surname><given-names>MA</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name><name><surname>Neefjes</surname><given-names>JJ</given-names></name><name><surname>Filippov</surname><given-names>DV</given-names></name><name><surname>van der Marel</surname><given-names>GA</given-names></name><name><surname>Dantuma</surname><given-names>NP</given-names></name><name><surname>Overkleeft</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo</article-title><source>Chemistry &amp; Biology</source><volume>13</volume><fpage>1217</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2006.09.013</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Durfee</surname><given-names>LA</given-names></name><name><surname>Huibregtse</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A cotranslational ubiquitination pathway for quality control of misfolded proteins</article-title><source>Molecular Cell</source><volume>50</volume><fpage>368</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.03.009</pub-id><pub-id pub-id-type="pmid">23583076</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>L</given-names></name><name><surname>Refahi</surname><given-names>Y</given-names></name><name><surname>Wightman</surname><given-names>R</given-names></name><name><surname>Landrein</surname><given-names>B</given-names></name><name><surname>Teles</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>KC</given-names></name><name><surname>Meyerowitz</surname><given-names>EM</given-names></name><name><surname>Jönsson</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cell size and growth regulation in the <italic>Arabidopsis thaliana</italic> apical stem cell niche</article-title><source>PNAS</source><volume>113</volume><fpage>E8238</fpage><lpage>E8246</lpage><pub-id pub-id-type="doi">10.1073/pnas.1616768113</pub-id><pub-id pub-id-type="pmid">27930326</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>S</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name><name><surname>Dillin</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Differential scales of protein quality control</article-title><source>Cell</source><volume>157</volume><fpage>52</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.03.007</pub-id><pub-id pub-id-type="pmid">24679526</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Skotheim</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A G1 sizer coordinates growth and division in the mouse epidermis</article-title><source>Current Biology</source><volume>30</volume><fpage>916</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2019.12.062</pub-id><pub-id pub-id-type="pmid">32109398</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yau</surname><given-names>R</given-names></name><name><surname>Rape</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The increasing complexity of the ubiquitin code</article-title><source>Nature Cell Biology</source><volume>18</volume><fpage>579</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1038/ncb3358</pub-id><pub-id pub-id-type="pmid">27230526</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zatulovskiy</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Berenson</surname><given-names>DF</given-names></name><name><surname>Topacio</surname><given-names>BR</given-names></name><name><surname>Skotheim</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cell growth dilutes the cell cycle inhibitor Rb to trigger cell division</article-title><source>Science</source><volume>369</volume><fpage>466</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1126/science.aaz6213</pub-id><pub-id pub-id-type="pmid">32703881</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zetterberg</surname><given-names>A</given-names></name><name><surname>Killander</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1965">1965</year><article-title>Quantitative cytochemical studies on interphase growth</article-title><source>Experimental Cell Research</source><volume>39</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/0014-4827(65)90003-0</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinder</surname><given-names>O</given-names></name><name><surname>Shapiro</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1971">1971</year><article-title>Effect of cell size on epinephrine- and ACTH-induced fatty acid release from isolated fat cells</article-title><source>Journal of Lipid Research</source><volume>12</volume><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/S0022-2275(20)39551-1</pub-id><pub-id pub-id-type="pmid">4322519</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75393.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Postovit</surname><given-names>Lynne-Marie</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y72wh86</institution-id><institution>Queens University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2021.11.09.467936" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2021.11.09.467936"/></front-stub><body><p>This important study reports a previously undocumented role for ubiquitin-proteasome system (UPS)-mediated protein turnover in size control in human cells. The authors show that large cells undergo size compensation by actively reducing their rate of growth and this effect is shown to be mediated by an increase in the rate of proteasome-mediated degradation. The experiments are well controlled, and the conclusions of the study are compelling and well supported by the data. Overall the paper increases our knowledge related to size control mechanisms in dividing and non-dividing cells.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75393.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Postovit</surname><given-names>Lynne-Marie</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y72wh86</institution-id><institution>Queens University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Edgar</surname><given-names>Bruce A</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r0ha626</institution-id><institution>University of Utah</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.11.09.467936">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.11.09.467936v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Large cells activate global protein degradation to maintain cell size homeostasis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer , including Bruce A Edgar as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Marianne Bronner as the Senior Editor. We apologize for the very long time this manuscript has taken in review.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Overall, the reviewers appreciated the significance of the new central finding, that protein degradation can be used as a mechanism to regulate cell size, and compensate for changes in division rates. However, for several reasons, the reviewers were not entirely confident in the results used to support this interesting mechanism, and so they have requested major revisions with new data and new data analyses.</p><p>Essential revisions (for the authors):</p><p>1) As reviewer 2 noted: &quot;something is wrong with the cell size measurements in Figure 2 because many cells basically have almost negligible size (near 0) while others have sizes up to 5 or 6 arbitrary units. It makes no sense that there should be a 10-fold or even 100-fold range in cell sizes… The data supporting higher rates of protein degradation per unit mass in large cells suffers from a similar problem as Figure 3E has the same issue as Figure 2 with too many tiny 'cells'.&quot; Please address this concern with an explanation, and if necessary, add new data or a new analysis of existing data.</p><p>2) Review #1 was concerned that only CDK2 inhibition was used as a tool to alter rates of cell cycle progression. The reviewer reasonably requests that an alternate tool be used to demonstrate that the effect on protein degradation is a general one, and not a direct and specific effect of CDK2 inhibition.</p><p>3) Reviewer #3 makes the important point (2) that &quot;If translation rate is higher in large cells, then basal protein degradation may also be correspondingly higher.&quot; Some control experiments should be provided that rule out this trivial possibility.</p><p>4) The reviews mention many other small and large changes that could improve the paper. Please consider these and address them at your discretion.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The paper falls short of demonstrating, or proposing, a molecular mechanism explaining the connection between cell size and protein degradation. This is not strictly necessary provided the basic phenomenon is definitely demonstrated, but additional data on mechanism would certainly elevate the paper considerably.</p><p>1. A very relevant paper on cell growth from Mu, Meittinen et al. (PNAS 2020) should be discussed and cited. This paper concludes that larger cells (of a different type) do not grow slower.</p><p>2. The figure legends generally have too little information about the experimental design, making it difficult to interpret the results. In some cases the relevant details about an experiment can be found in the methods, but not always. Please review the figure legends and add detail explaining how the experiment was done.</p><p>3. Figure 1 C presents &quot;early&quot; and &quot;late&quot; cells. Please denote the time/treatments these cells received.</p><p>4. Figure 3A is not really informative, since the change in cell mass is shown in AU rather than % of cell mass. Please show this as a fraction of cell mass.</p><p>5. Figure 3E is essentially a control example, but it is presented as a result. To support the hypothesis that this data shows more active proteasomes in larger cells, the data should: (a) include a similar dataset for SNS-032 treated cells; and (b) be normalized to cell sizes. From the data presented, it looks like active proteasome amounts scale linearly with cell size, and that larger cells do not have a fractionally high number of active proteasomes (per unit mass). This doesn't support the authors' hypothesis.</p><p>6. The authors' general conclusions might be tested by decreasing protein degradation or ubiquitination in the CDK2-inhibited cells. This would be predicted to further increase cell size.</p><p>7. Line 467-468: were the deltaK48-polyUB data in Figure 4 supplement 1 also normalized to cell volumes? Please clarify in the figure legend and/or methods.</p><p>8. The authors present a number of assays with immunodetection of K48-polyUB. I believe what they are measuring here is k48-polyubiquitinated proteins of all sorts. If so, they should refer to this metric as &quot;K48-polyUB-protiens&quot; in the text and figures.</p><p>9. Figure 3F needs to present statistical differences between the SNS-032-treated and control cells.</p><p>10. It was not clear to me how Figure 4 supplement 2 supports the conclusions of the paper. The authors should explain this better, or leave it out.</p><p>11. It is interesting that generally cells with larger size have higher protein degradation rate (S, G2 cells degrade proteins faster than early G1), except that G1/S cells possess the highest degradation rate among all cell cycle phases. Since G1/S cells are not in the phase with the largest cell size, this is rather puzzling. Does it suggest that protein degradation rate is primarily regulated by some other mechanism, like CDK activity, rather than cell size? Please comment.</p><p>12. In Figure 1B, the authors characterize the average cell size changes after rapamycin or SNS-032 treatment. Because cell size is a distribution over a range, simply averaging all cells together may obscure some informational content. It is probably preferable to plot the distribution of cell sizes (e.g. dot plots or violin plots), comparing control and treatment groups.</p><p>13. Figure 1D shows that the nuclear area drops around G1/S when Cdk2 inhibitor is used. However, when they replotted the data by aligning cells based on the timeline relative to G1/S, this phenotype is not obvious anymore (Figure 1E). Please comment on why this is.</p><p>14. Page 3, line 112: should the reference be to Figure 1B?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1. While the main conclusion of the paper that larger cells size compensate by increased proteasome-dependent protein turnover is supported by key experiments (Figure 3 D,E; Figure 4 A,E) the link to cell size is largely correlative, as supported by exploiting stochastic size variation in unperturbed cells and treatment with the CDK2 inhibitor in a perturbed context. To my mind, an important control would be to look in the situation where cells become large and size compensation does not occur, i.e., CDK6 inhibitor treated cells. The authors' model predicts that there should be no increase in proteasomal activity in the CDK6 inhibitor-treated cells. It seems likely that authors would have considered this experiment given their published observation that CDK6 inhibition is accompanied by unrestrained growth without size compensation.</p><p>2. One mechanism that could contribute to the increased rate of degradation is abortive translation that requires proteasome mediated clearance of partial translation products. It has long been known that turnover of nascent translated proteins accounts for a substantial fraction of proteasomal flux (~50% if I recall correctly). If translation rate is higher in large cells, then basal protein degradation may also be correspondingly higher. Although the size normalization of K48 chain turnover suggests that additional degradation indeed occurs in large cells, a possible further control to test this idea would be to treat cells with an acute sub-lethal dose of cycloheximide to slow translation followed by measurement of proteasome activity. Alternatively, treatment of cells with a low dose proteasome inhibitor would be predicted to reduce size compensation and allow cells to become larger.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75393.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions (for the authors):</p><p>1) As reviewer 2 noted: &quot;something is wrong with the cell size measurements in Figure 2 because many cells basically have almost negligible size (near 0) while others have sizes up to 5 or 6 arbitrary units. It makes no sense that there should be a 10-fold or even 100-fold range in cell sizes…… The data supporting higher rates of protein degradation per unit mass in large cells suffers from a similar problem as Figure 3E has the same issue as Figure 2 with too many tiny 'cells'.&quot; Please address this concern with an explanation, and if necessary, add new data or a new analysis of existing data.</p></disp-quote><p>The reviewer is correct that the original scatter plots in Figure 2 gave a misleading impression of the cell size distribution, suggesting an implausible 10-fold to 100-fold variation in cell sizes – a false impression that was unfortunately caused by our poor choice of data representation. The previous visualization inadvertently emphasized the presence of rare image processing cell-segmentation errors that make the appearance of extremely-sized “cells”. Although these outliers are rare in our scatter plots, they are visually prominent, leading to an overestimation of the actual cell size range. It is worth noting that when processing thousands of images to extract single cell data, the presence of such rare segmentation errors is currently inevitable. While these false positives do not affect statistics nor overall trends, they do jump to eye when presented as scatter plots, especially in the sparse regions of the scatter plots.</p><p>To correct this misleading representation, we now revised Figure 2 to more effectively depict the actual cell size distributions in our data and de-emphasized the outliers laying at the extremes. The inclusion of cell size histograms further clarifies the true distribution of cell sizes. To rectify the misleading representation in the original manuscript, we have implemented the following changes:</p><list list-type="bullet"><list-item><p>Data Representation: We have applied a transparency setting to the scatter plot data points. This method offers a more accurate depiction of the data distribution.</p></list-item><list-item><p>Cell Size Histograms: We have included histograms in Figure 2A to illustrate the actual distribution of cell size. This provides a clearer view of the range of our measurements.</p></list-item><list-item><p>Normalization: We now present cell size data normalized to the average G1 size in control conditions, whenever applicable. This normalization helps to interpret cell size measurements within a more meaningful context, allowing for better comparison across different cell cycle stages and treatment conditions.</p></list-item></list><p>By implementing these changes, we aim to provide a more accurate representation of our data and address the reviewer's concerns effectively. These adjustments have also been applied to Figure 3E (currently Figure 3F) to ensure consistency and clarity across our analyses.</p><p>As clarified by the revised figure, our cell size measurements show a much narrower and biologically plausible range (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref> and revised Figure 2A). For example, when comparing the average of G1 phase cells to that of the G2+M phase, we observe a ~1.5-fold change in size, which aligns with typical expectations.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Cell size distribution in DMSO control condition.</title><p>A. Cell size histogram with median (solid line) and 1st and 99th percentiles (dashed lines) labeled. B. DNA histogram showing classification of cells to different cell cycle stages. C. Cell size distribution plotted separately for G1, S, and G2+M cells with their median labeled by solid lines of the corresponding color.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75393-sa2-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>2) Review #1 was concerned that only CDK2 inhibition was used as a tool to alter rates of cell cycle progression. The reviewer reasonably requests that an alternate tool be used to demonstrate that the effect on protein degradation is a general one, and not a direct and specific effect of CDK2 inhibition.</p></disp-quote><p>We accept the reviewer’s critique. In the revision, we explored additional perturbations that slow rates of cell cycle progression, and these new data have further strengthened our conclusions.</p><p>Generally speaking, cell cycle lengthening can be caused by delaying progression through G1, S, or G2/M phases. With respect to G1, the three primary targets are CDK2, CDK4, and CDK6. However, in the context of the present study, only CDK2, but not CDK4/6, is an appropriate target. As described in our previous studies (Ginzberg et al., 2018, doi.org/10.7554/<italic>eLife</italic>.26957; Tan et al., 2021, doi.org/10.1016/j.devcel.2021.04.030), inhibiting CDK2 extends the duration of G1, leading to an initial increase in cell size that is subsequently counteracted by a compensatory slowdown in growth rate. In contrast, inhibiting CDK4/6 not only affects cell cycle progression but also alters the cell's target size. Thus, we applied CDK4/6 inhibition (by palbociclib) as an additional “negative control” in the revision. Indeed, we found that although CDK4/6 inhibition significantly increases cell size and protein degradation rates, the two maintain a similar linear relationship as the control (Figure 3—figure supplement 4A-C).</p><p>We also expanded our study and included in our revision not only G1 perturbations, but also perturbations that lengthen the cell cycle by slowing down progression through S phase and mitosis. We identified chemicals from a previous in-house screen (Kaufman et al., 2022, doi.org/10.1038/s41467-022-30008-0) that significantly altered cell size while extending the S phase or G2/M phase, without significantly disrupting cell size uniformity. Another criterion was to avoid perturbations that directly disrupt the structural integrity (e.g., DNA, cytoskeleton) of the cell. This allowed us to employ two alternate compounds: JNJ-26854165, which slows S phase progression, and barasertib, which inhibits mitosis. The new data (Figure 3—figure supplement 4D-I) revealed that inhibiting progression of either S or M phase triggered a compensatory increase in global protein degradation, as evidenced by elevated levels of ΔK48-polyUb. This effect is particularly pronounced in the specific cell cycle stages targeted by the inhibitors. And like CDK2 inhibition, these increases in ΔK48-polyUb are disproportionately larger than the corresponding increases in cell size, suggesting an active upregulation of protein degradation beyond what would be expected solely due to increased cell size. These new results suggest that the activation of protein degradation functions as a general compensatory mechanism for oversized cells to maintain size homeostasis, regardless of the specific cell cycle stage affected.</p><p>These new data and analyses have been incorporated in the revised manuscript line 224-253.</p><disp-quote content-type="editor-comment"><p>3) Reviewer #3 makes the important point (2) that &quot;If translation rate is higher in large cells, then basal protein degradation may also be correspondingly higher.&quot; Some control experiments should be provided that rule out this trivial possibility.</p></disp-quote><p>The reviewer's insightful comment raises two important questions:</p><list list-type="roman-upper"><list-item><p>Is the higher rate of protein degradation in large cells simply due to larger cells having more proteins, rather than a compensatory mechanism?</p></list-item><list-item><p>Which types of protein are degraded: newly synthesized nascent proteins (canonically associated with protein quality control) or non-nascent/long-lived proteins?</p></list-item></list><p>Addressing the first question: While we do observe a positive correlation between cell size and protein degradation rate, cells under CDK2 inhibition show a superlinear increase in ΔK48-polyUb relative to their increase in cell size. This is particularly evident when examining different cell cycle stages (Figure 3D). While control cells in G1, S, and G2+M phases show a positive correlation between size and ΔK48-polyUb, CDK2 inhibited cells sit above this trend, indicating an increase in protein degradation beyond what would be expected from increased cell size alone. In addition, naturally large cells at G1/S transition also show higher efficiency of protein degradation (i.e., degradation rates per unit mass) compared to similarly-sized or even larger cells in S and G2 (Figure 4E). These observations are not consistent with the simple model that large cells have higher protein degradation simply because of their higher translation rate. In the new manuscript, we now better present these points in Results line 203-253 and line 296-314, and in Discussion line 341-365.</p><p>To address the second question, we followed the reviewer's suggestion and measured proteasome-mediated protein degradation rates in cells subject to an acute, sub-lethal dose of cycloheximide (CHX, 3 μM for 3h). We applied this treatment with or without CDK2 inhibition (SNS+/-). This approach allowed us to discriminate degradation of nascent (CHX-sensitive) and non-nascent (CHX-insensitive) proteins:</p><list list-type="bullet"><list-item><p>ΔK48-polyUb in non-CHX-treated cells (CHX-) reflects degradation of both nascent and non-nascent proteins</p></list-item><list-item><p>ΔK48-polyUb in CHX-treated cells (CHX+) reflects degradation of only non-nascent proteins Our results (Figure 3G, Figure 3—figure supplement 6) show:</p></list-item></list><list list-type="bullet"><list-item><p>ΔK48-polyUb significantly decreases with CHX treatment, consistent with previous understanding that nascent proteins constitute a substantial fraction of the proteasomal flux.</p></list-item><list-item><p>In CHX+ conditions, SNS treatment significantly increases (+120%) degradation of non-nascent proteins in cells at the G1/S transition, but not at or to a much smaller extent at other cell cycle stages.</p></list-item><list-item><p>SNS treatment increases ΔK48-polyUb across all cell cycle stages in CHX- conditions, indicating increased degradation of both nascent and non-nascent proteins, with significant contribution from nascent proteins.</p></list-item></list><p>These findings suggest that compensatory protein degradation involves both nascent and non-nascent proteins, with the balance depending on the cell cycle stage. Notably, this indicates that degradation of nascent proteins, typically associated with protein quality control, can be employed for growth rate modulation and control of cell size homeostasis. At the G1/S transition, a time point of stringent size control, large cells appear to activate degradation of non-nascent proteins to modulate growth rate. These new results are now incorporated in the revised manuscript line 278-295.</p><p>Regarding the reviewer’s suggestion to use a low-dose proteasome inhibitor, we have actually performed this very experiment in a previous publication (Kafri et al., 2013, doi: 10.1038/nature11897). Consistent with the thesis of the present study, low-dose proteasomal inhibition not only decreased cell size but also significantly increased cell size variance, particularly at the G1/S transition. Those results are consistent with our thesis that protein degradation serves to maintain cell size homeostasis.</p><p>In the current study, we used short-term (30 min) treatment with the proteasome inhibitor CFZ as a tool to quantify protein degradation rates. This short-term inhibition did not significantly affect cell size or cell cycle distribution (Figure 3—figure supplement 2). As for the suggestion for long-term proteasome inhibition, while the experiments can be interesting, we feel they may not be compatible with the goals and context of our present study. Because cell cycle progression is directly controlled by proteasome-mediated cyclin degradation, it would be challenging to distinguish between the inhibitor's effects on global protein metabolism, cell cycle perturbation, and cell size regulation.</p><disp-quote content-type="editor-comment"><p>4) The reviews mention many other small and large changes that could improve the paper. Please consider these and address them at your discretion.</p></disp-quote><p>We thank the reviewers for the additional suggestions. We respond to each point below.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The paper falls short of demonstrating, or proposing, a molecular mechanism explaining the connection between cell size and protein degradation. This is not strictly necessary provided the basic phenomenon is definitely demonstrated, but additional data on mechanism would certainly elevate the paper considerably.</p></disp-quote><p>We share the reviewer’s curiosity in the molecular mechanisms connecting cell size and protein degradation. From years long research on the subject, we think the mechanisms in play should involve three distinct layers: (1) cell size sensing – biophysical or biochemical mechanisms that allow individual cells to detect their own size; (2) cell size-dependent signal transduction – signaling pathways downstream of the size sensors that mediate signaling events (e.g., gene expression, phosphorylation, etc.) depending on cell size; and (3) effector mechanisms – processes that regulate proteasomal activity based on the size-dependent signaling.</p><p>Identifying these mechanisms has been, and continues to be, a central focus of our lab and the field. However, while we are committed to pursuing this goal, addressing the full scope of these questions will require years of research that extends beyond the scope of the current paper. It is worth noting that despite the discovery of cell size checkpoints in the 1960s by Killander and Zetterberg, the molecular mechanisms of cell size sensors and checkpoints remain not well understood today.</p><p>In the revised manuscript, we have expanded the Discussion section to address the open questions raised by our study and highlight the importance of future research in elucidating the precise molecular mechanisms underlying this newly identified cell size control pathway (line 388-392, line 371-379).</p><disp-quote content-type="editor-comment"><p>1. A very relevant paper on cell growth from Mu, Meittinen et al. (PNAS 2020) should be discussed and cited. This paper concludes that larger cells (of a different type) do not grow slower.</p></disp-quote><p>We thank the reviewer for pointing us to this very relevant paper. We now cite and discuss the paper in the revised manuscript (line 366-369).</p><disp-quote content-type="editor-comment"><p>2. The figure legends generally have too little information about the experimental design, making it difficult to interpret the results. In some cases the relevant details about an experiment can be found in the methods, but not always. Please review the figure legends and add detail explaining how the experiment was done.</p></disp-quote><p>We have revised figure legends and added more details of the experimental design.</p><disp-quote content-type="editor-comment"><p>3. Figure 1 C presents &quot;early&quot; and &quot;late&quot; cells. Please denote the time/treatments these cells received.</p></disp-quote><p>We have now defined early and late stage cells in the respective legend (currently Figure 1 – S1).</p><disp-quote content-type="editor-comment"><p>4. Figure 3A is not really informative, since the change in cell mass is shown in AU rather than % of cell mass. Please show this as a fraction of cell mass.</p></disp-quote><p>We agree with the reviewer that showing changes as a fraction of cell mass is more informative, and have modified the figures (Figure 3A, Figure 3—figure supplement 1) accordingly.</p><disp-quote content-type="editor-comment"><p>5. Figure 3E is essentially a control example, but it is presented as a result. To support the hypothesis that this data shows more active proteasomes in larger cells, the data should: (a) include a similar dataset for SNS-032 treated cells; and (b) be normalized to cell sizes. From the data presented, it looks like active proteasome amounts scale linearly with cell size, and that larger cells do not have a fractionally high number of active proteasomes (per unit mass). This doesn't support the authors' hypothesis.</p></disp-quote><p>We agree with the reviewer that the linear correlation of cell size and active proteasomes does not fully explain the mechanism for size-dependent compensatory degradation. However, as emphasized by the reviewer comment, our description in the original manuscript failed to clarify that.</p><p>To explain the higher efficiency of protein degradation in oversized cells, the relationship between cell size and proteasomal degradation may follow three simple possibilities:</p><list list-type="bullet"><list-item><p>Oversized cells have higher concentrations of total proteasomes.</p></list-item><list-item><p>Oversized cells have higher concentrations of active proteasomes.</p></list-item><list-item><p>Oversized cells have higher efficiency in degrading proteins per active proteasome.</p></list-item></list><p>While there is superlinear increased degradation and polyubiquitination in larger cells, we clarified in the revised manuscript that large cells did not show superlinear increases at the level of total proteasome content or active proteasomes (Figure 3E-F). These data are more consistent with the third possibility of an increased efficiency in protein degradation, and we make it clear in the manuscript that the question warrants further investigation (line 272-277).</p><disp-quote content-type="editor-comment"><p>6. The authors' general conclusions might be tested by decreasing protein degradation or ubiquitination in the CDK2-inhibited cells. This would be predicted to further increase cell size.</p></disp-quote><p>We thank the reviewer for the suggestion. A related experiment has been previously reported, where we measured cell size dynamics under the proteasome inhibitor MG132 (Kafri et al., 2013, doi: 10.1038/nature11897). This study revealed that proteasome inhibition not only caused cells to become larger but also increased cell size variability, particularly at the G1/S transition. These findings align with our proposed model, suggesting that compensatory degradation acts as a general mechanism to buffer natural cell size variations.</p><p>For the current study, we considered applying long-term proteasome inhibition (e.g., 24 hours) in combination with CDK2 inhibitors. However, since cell cycle progression is tightly regulated by proteasome-mediated degradation of key cell cycle regulators, we believe that long-term inhibition would complicate interpretation. Specifically, it would be difficult to distinguish whether observed changes in cell size were due to global alterations in protein metabolism or direct disruptions to cell cycle regulation. For this reason, we opted not to pursue long-term proteasome inhibition in this context.</p><disp-quote content-type="editor-comment"><p>7. Line 467-468: were the deltaK48-polyUB data in Figure 4 supplement 1 also normalized to cell volumes? Please clarify in the figure legend and/or methods.</p></disp-quote><p>The ΔK48-polyUb data shown in Figure 4—figure supplement 1B are not normalized to cell size or volume. We now better clarify this in its figure legend (line 981) and in the results (line 311-312).</p><disp-quote content-type="editor-comment"><p>6. The authors present a number of assays with immunodetection of K48-polyUB. I believe what they are measuring here is k48-polyubiquitinated proteins of all sorts. If so, they should refer to this metric as &quot;K48-polyUB-protiens&quot; in the text and figures.</p></disp-quote><p>The reviewer is correct. We use “K48-polyUB” as an abbreviation for K48-linked polyubiquitinated proteins. We define this abbreviation when it first appears in the text (line 178-179) and in figure legends.</p><disp-quote content-type="editor-comment"><p>6. Figure 3F needs to present statistical differences between the SNS-032-treated and control cells.</p></disp-quote><p>As suggested, we have now included statistical significance for comparisons between SNS-032treated and control cells for each cell cycle stage in the figure legend (currently Figure 3D legend).</p><disp-quote content-type="editor-comment"><p>7. It was not clear to me how Figure 4 supplement 2 supports the conclusions of the paper. The authors should explain this better, or leave it out.</p></disp-quote><p>We appreciate the reviewer’s comment and understand the need for clarity.</p><p>The data presented in Figure 4—figure supplement 2A-B are derived from live-cell tracking experiments under mTOR inhibition. The key insight offered by the figure extends from the contrast between panels A and C. In panel A, mTORinhibited large and small cells show converging growth rates prior to the G1/S transition. However, as shown in panel C, mTOR-inhibited large cells synthesize proteins at a much faster rate than smaller cells. This discrepancy indirectly points to an elevated level of protein degradation in large cells prior to the G1/S transition. This result corroborates the more direct measurements of protein degradation presented in the main Figure 4.</p><p>In the revised manuscript, we have clarified the relevant Results section to better explain these points (line 315327). While reviewer #3 suggested including these data in the main figure, we believe it is more appropriate to keep it as a supplement to avoid overcomplicating the main figure layout.</p><disp-quote content-type="editor-comment"><p>8. It is interesting that generally cells with larger size have higher protein degradation rate (S, G2 cells degrade proteins faster than early G1), except that G1/S cells possess the highest degradation rate among all cell cycle phases. Since G1/S cells are not in the phase with the largest cell size, this is rather puzzling. Does it suggest that protein degradation rate is primarily regulated by some other mechanism, like CDK activity, rather than cell size? Please comment.</p></disp-quote><p>We thank the reviewer for pointing out this interesting phenomenon. We were indeed surprised to find that G1/S cells in control show the highest global protein degradation rates despite being generally smaller than S and G2 phase cells (Figure 4A-B). Figure 4E better demonstrates protein degradation efficiency as a function of both the cell size and cell cycle stage. In particular, large cells at G1/S transition show the highest protein degradation efficiency (i.e., degradation rates per unit mass). These data suggest that protein degradation rates may be regulated by both cell size and the cell cycle, and possibly directly regulated by the cell cycle machinery or other cell cycle events. We now comment about this and highlight these important questions in the discussion (line 380-392).</p><disp-quote content-type="editor-comment"><p>9. In Figure 1B, the authors characterize the average cell size changes after rapamycin or SNS-032 treatment. Because cell size is a distribution over a range, simply averaging all cells together may obscure some informational content. It is probably preferable to plot the distribution of cell sizes (e.g. dot plots or violin plots), comparing control and treatment groups.</p></disp-quote><p>We thank the reviewer for the suggestion. The previous Figure 1B-C panels were reproduced from our earlier work (Ginzberg et al., 2018, doi.org/10.7554/<italic>eLife</italic>.26957) to illustrate the assay to a general audience. We agree with the reviewer’s suggestion that presenting the distribution of cell sizes can provide additional clarity. However, considering reviewer #3’s recommendation to omit these figures and cite the original publication instead, we have moved these panels to the supplement (now Figure 1—figure supplement 1). For consistency in the figure presentation, we have retained the original figure format as in the published version. We will consult with the editorial team regarding the use and reformatting of these reproduced figures.</p><disp-quote content-type="editor-comment"><p>10. Figure 1D shows that the nuclear area drops around G1/S when Cdk2 inhibitor is used. However, when they replotted the data by aligning cells based on the timeline relative to G1/S, this phenotype is not obvious anymore (Figure 1E). Please comment on why this is.</p></disp-quote><p>We thank the reviewer for this insightful observation.</p><p>Figure 1D-E are derived from live-cell imaging experiments and are intended to illustrate the phenomenon of size dependent compensatory growth control. Under CDK2 inhibition, cells spend a longer time in G1 but compensate by reducing their growth rate, ultimately entering the S phase at a size comparable to that of control cells. This conclusion is based on growth rate measurements averaged across the cell cycle.</p><p>As the reviewer noted, Figure 1D shows a decrease in the nuclear area as cells approach the G1/S transition under CDK2 inhibition. However, when the data is synchronized based on the G1/S transition (Figure 1E), this decrease seems less apparent. This may be partly due to the two figures being displayed at different timescales.</p><p>Nevertheless, while the data allows us to conclude the overall slowdown of the growth rate in CDK2-inhibited cells averaged across the entire cell cycle, the current datasets do not provide sufficient statistical power to conclude whether CDK2-inhibited cells exhibit particularly prominent growth slowdown during a short period around G1/S transition compared to other cell cycle stages. Thus we have decided not to comment further on this aspect in the manuscript. However, this is an intriguing area for future investigation.</p><disp-quote content-type="editor-comment"><p>11. Page 3, line 112: should the reference be to Figure 1B?</p></disp-quote><p>Yes. Thank you. We have now corrected this typo.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1. While the main conclusion of the paper that larger cells size compensate by increased proteasome-dependent protein turnover is supported by key experiments (Figure 3 D,E; Figure 4 A,E) the link to cell size is largely correlative, as supported by exploiting stochastic size variation in unperturbed cells and treatment with the CDK2 inhibitor in a perturbed context. To my mind, an important control would be to look in the situation where cells become large and size compensation does not occur, i.e., CDK6 inhibitor treated cells. The authors' model predicts that there should be no increase in proteasomal activity in the CDK6 inhibitor-treated cells. It seems likely that authors would have considered this experiment given their published observation that CDK6 inhibition is accompanied by unrestrained growth without size compensation.</p></disp-quote><p>We appreciate the reviewer's suggestion and have incorporated measurements with a CDK4/6 inhibitor (Figure 3—figure supplement 4A-C). CDK4/6 inhibition led to a significant increase in cell size. And aligning with the reviewer expectation, while protein degradation rates did increase with CDK4/6 inhibition, this increase was proportional to the increase in cell size. This is in contrast to the phenotype of CDK2 inhibition, where the increase in degradation rates was superlinear and exceeded the expectation based on cell size alone. Taken together, the new data aligns with the reviewer’s suggestion that compensatory degradation is not activated in CDK4/6-inhibited cells that reprograms a larger target size without inducing compensatory growth slowdown. These new results are now incorporated in the revised manuscript line 224-234.</p><disp-quote content-type="editor-comment"><p>2. One mechanism that could contribute to the increased rate of degradation is abortive translation that requires proteasome mediated clearance of partial translation products. It has long been known that turnover of nascent translated proteins accounts for a substantial fraction of proteasomal flux (~50% if I recall correctly). If translation rate is higher in large cells, then basal protein degradation may also be correspondingly higher. Although the size normalization of K48 chain turnover suggests that additional degradation indeed occurs in large cells, a possible further control to test this idea would be to treat cells with an acute sub-lethal dose of cycloheximide to slow translation followed by measurement of proteasome activity. Alternatively, treatment of cells with a low dose proteasome inhibitor would be predicted to reduce size compensation and allow cells to become larger.</p></disp-quote><p>We thank the reviewer for the suggestion. Please refer to our detailed response above to essential point #3.</p></body></sub-article></article>